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INTERACTIONS OF NEURONS, ASTROCYTES AND MICROGLIA WITH
HUCB CELL POPULATIONS IN STROKE MODELS: MIGRATION,
NEUROPROTECTION AND INFLAMMATION

Lixian Jiang

ABSTRACT

Previous studies demonstrated that intravenous administration of human
umbilical cord blood (HUCB) cells could improve behavioral and neurological
recovery of stroked animals following middle cerebral artery occlusion (MCAO).
In addition, HUCB cell recipients had less of an inflammatory response with less
leukocyte infiltration. In these studies we explored how HUCB cells change the
inflammatory response of neurons, astrocytes, and microglia to hypoxia/ischemia.
Initiation of the inflammatory response occurs with the expression of chemokines.
We determined that monocyte chemoattractant protein-1 (MCP-1) and
macrophage inflammatory protein 1 alpha (MIP-1α), which are upregulated in the
brain early after a stroke, induce migration of HUCB cells to the site of injury.
Neutralizing these chemokines with antibodies prevented migration in an in vitro
migration assay. We next explored the interaction of the whole HUCB
mononuclear cell fraction, as well as subpopulations from within the mononuclear
xii

fraction (T cell alone, B cell alone, and monocytes/macrophage alone) with
cultures of enriched neurons, astrocytes or microglia exposed to hypoxia in an
oxygen, glucose deprivation paradigm. We showed that HUCB cells increased
the cell viability of neurons and astrocytes, while decreasing cell viability of
microglia. There was also a change in the cytokine secretion profile from the cells
exposed to HUCB cells under hypoxic conditions. These results suggested that
chemokines, MCP-1 and MIP-1α increased in stroked brain, and they played an
important role in recruitment of HUCB into the CNS after intravenous
administration. Once inside the brain, HUCB could suppress the immune
response by promoting microglial death and modulating the function of astrocytes.
In addition, HUCB cells provide neuron protection against the injury caused by
stroke. However, it is unlikely to contribute the effect of HUCB to a single
population of HUCB.

xiii

CHAPTER ONE
INTRODUCTION

1.1 Characterizing Cord Blood
Human umbilical cord blood (HUCB) is a rich source of stem cells that have
been used to reconstitute immune cells and blood lineages for the treatment of
hematological diseases (1). The first clinical use of HUCB cells was in 1988 on a
patient with Fanconi anemia (2). Since that time, more than 1000 transplants
have been performed around the world in treatment of hematopoietic and genetic
disorders including lymphoid and myeloid leukemia, Fanconi anemia, aplastic
anemia, Hunter syndrome, Wiskott-Aldrich syndrome, beta- thalassemia, and
neuroblastoma (3). Cord blood is the blood contained in the umbilical vein within
the placental stump that is normally discarded after delivery of the neonate. Cord
blood can be collected after clamping and cutting the umbilical cord, immediately
after the birth of the baby. Compared to bone marrow, HUCB transplantation has
less morbidity and mortality (4). Cord blood banks are being established in many
countries including the United States and standard protocols for sample
processing and storage developed (5).

The actual part of the cord blood that is used for cell transplantation is the
“mononuclear fraction”, a fraction of the blood containing mainly mononuclear
1

cells that is obtained by cell gradient separation techniques. Included in this
fraction are the stem cells (HSC), which are multi-potential and can proliferate
and differentiate into all lineages of haematopoietic cells. HSC cells are usually
CD34 positive (+) cells, although CD34+ cells constitute a very heterogeneous
cell population. The majority of CD34+ cells express both HLA-DR and CD38
antigens, while the most primitive HSC lack the expression of HLA-DR and CD38
(6,7). CD34+ cells can further differentiate into three different progenitor
populations. The first is the multipotent progenitors, or the colony forming unit multipotential (CFU-Mix) progenitors. The second one is the myeloid progenitors,
or colony forming unit granulocyte-macrophage (CFU-GM) progenitors. The third
one is erythroid progenitors, and its cultures are characterized as colony forming
unit granulocyte-macrophage-erythroid (CFU-E) and burst forming unit-erythroid
(BFU-E) colonies. CFU-MIX progenitors express low/undetectable levels of both
CD45RA and CD71, and CFU-GM progenitors are CD34+ CD45RA+ CD71lo cells,
while erythroid progenitors are marked with CD34+ CD45RAlo CD71+(8,9). The
CD34+ cell content in HUCB has been shown to be around 1 percent of the
mononuclear fraction (10). One milliliter HUCB there are about 8,000 primitive
erythroid progenitors (BFU-E), between 13,000 and 24,000 myeloid progenitors
(CFU-GM), and between 1,000 and 10,000 multipotent progenitors (CFU-Mix) (11,
12).

Another component of cord blood cells is the lymphocyte, which is comprised
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of T and B cells, and accounts for almost 41 percent of the mononuclear fraction
of HUCB (13). T cells are defined by the expression of the CD3 molecules,
which roughly are divided into CD4 or CD8 positive cells. CD4 positive T cells are
around 55% of the T cell population, and CD8 positive cells account for the
remaining 45% (14). The proportion of CD4 and CD8 reflects the maturity of T
cells. In development, the ratio of CD4 to CD8 T cells progressively increases
over time at least till subjects are adult (15). Actually, in the T cells population
there are also a small number of cells that express CD 16 and/or CD56 without
co-expression of CD3. These cells are Natural Killer (NK) cells, and they are
important against cancer for killing cells (16). In contrast, B cells are defined by
the expression of CD19, a specific marker of B cell lineage (17), which starts to
be expressed from the differentiation of B cell progenitors, continues on pre-B
cell, and all the way to mature B cells (17). B cells are about 20% of HUCB, and
decline in adulthood (18).

Monocytes are also a component of the mononuclear faction, and they make
up the remaining portion of the HUCB mononuclear fractions (19). Monocytes are
derived from committed myeloid progenitor cells, circulate in the blood and enter
tissues to become resident tissue macrophage. Monocytes can be isolated by
flow cytometry according to their cell surface antigens CD11b, CD18, CD14, and
CD16. CD11b /CD18 are receptors on the surface of monocytes. They interact
with intercellular adhesion molecule I on the endothelium and localize monocytes
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to the sites of infection (20). Once monocytes enter different tissues, they
express certain enzymes, and can non-specifically take up particles such as
colloidal carbon, and specific endocytic receptors (21). Dendritic cells (DC) are
antigen presenting cells, and can activate naïve T cells. They account for a very
small portion of HUCB. They can be generated in vitro not only from CD34+
haemotopoietic stem cells in bone marrow or cord blood (22), but also from
peripheral blood CD14+ monocytes with IL-4 and GM-CSF stimulation (23).
Immature DC cells are CD1a positive cells, and when they get more mature, they
express CD83, CD80 and CD86 (24). These markers are also expressed by
monocytes.

In summary, HUCB mononuclear fraction is a very heterogeneous population
that is roughly divided into T cells, B cells and monocytes, and each
subpopulation takes one third of the whole mononuclear fraction of HUCB. Stem
cells as well as DC cells only account for 1-3% of this HUCB fraction.

1.2 Cord Blood as a Treatment for CNS injury
Since human umbilical cord blood (HUCB) cells is rich in hematopoietic stem
cells, it is possible for these cells to proliferate, differentiate into neural like cells
and replace the cell loss caused by stroke. When HUCB cells were directly
delivered into rodents subjected to MCAO, recipient animals showed an
improved neurological and behavioral recovery compared with non-transplanted
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animals. Animals with permanent MCAO given 1,000,000 HUCB cells
intrastriatally were significantly less active than nontransplanted animals during
both dark and light phases of the light cycle; activity of transplanted animals was
similar to their novel baseline behavior compared to sham controls. Further
transplanted animals learned to stay on the platform in the passive avoidance
task significantly more quickly than the animals with permanent occlusion and no
transplant. In addition, transplanted animals had better behavioral recovery in the
elevated body swing test and step test compared to nontransplanted animals
(25).

We and other laboratories also found this functional improvement could be
achieved with intravenous (i.v.) HUCB administration (26). For example, Chen
infused HUCB via tail vein 24 hours or 7 days after transient MCAO. The animals
with HUCB administered at 24 hours post stroke had improved performance on
the rotarod test and modified neurological severity score (mNSS) compared to
control animals, while animals treated with HUCB 7days after MCAO only
improved on the rotarod test but not the mNSS, suggesting the importance of
early intervention (26). When intraparenchymal administration was compared to
i.v. administration, both treatment routes promoted significant functional
improvement compared with stroke only animals (25). The animals that received
HUCB learned faster than nontransplanted animals (p<0.05). Interestingly, after 2
months only i.v. injected animals maintained functional improvements,
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particularly in the Step test. From a practical stand point, even though
intravenous administration had the same therapeutic effect as direct
administration, it has the great advantage of being more easily delivered.

The dose effect of HUCB administration after MCAO was also studied (27).
Significant reductions in spontaneous activity were observed in animals treated
with 106 or higher doses of cord blood cells in comparison to media treated
controls. Reductions in elevated body-swing bias and improvements in the Step
test were optimal at 107 cells and did not improve further at higher doses (27).
However, the higher the dose of cells, the smaller the infarct size in the stroked
animals.

Improved outcome was also observed when HUCB cells were administered
to animals that underwent hemorrhagic stroke (28). HUCB was delivered by
intravenous infusion into animals with hemorrhagic injury induced by intrastriatal
injections of collagenase. The animals were subjected to a battery of neurological
and behavioral tests at 1 day after injury, which was followed by the
administration of umbilical cord blood. The functional recovery was tested at 6,
and 13 day post HUCB infusion. HUCB significantly improved behavioral
recovery in the Step test at day 6, and elevated body-swing test at day 13 after
intravenous administration, while improved neurological scores were observed
day 6 to day 13 (28).

6

The function of HUCB cells was also evaluated in rats with spinal cord injury
induced by hemicompression at T8/9 with a calibrated aneurysm clip (29). One
million HUCB cells were infused into animals through the tail vein at day 1 or day
5 following spinal cord injury. Spontaneous activities of animals were monitored
with a digital camera for 3 weeks, and the behaviors were scored by the standard
developed by Basso, Beattie and Bresnehan (30). It was found that functional
improvement was progressive with time in all spinal cord injury groups, while
animals treated with HUCB at day 5 after spinal cord injury had a better
functional improvement than animals that received HUCB at day 1 after injury or
the control group. No significant differences were observed between animals that
received HUCB at day 1 after injury and the control group at any time point.
Histological examination revealed that HUCB did migrate into the injury site, and
there were more cells in animals that received HUCB at day 5 after injury than
animals that received HUCB at day 1 after injury. The data suggested that the
functional improvement at least partially depends on how many HUCB migrated
into the injury site (29).

Amyotrophic lateral sclerosis (ALS) is a severe CNS disease with diffuse
motor neuron degeneration. There are no effective treatments for this disease at
the moment. Recently, HUCB was delivered into transgenic ALS mice through
intravenous administration, and the functional recovery was examined (31).
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Animals receiving HUCB had a longer life span compared to control animals.
HUCB cells were found in the degenerating region of the brain and spinal cord,
and some exhibited neural phenotypes. There, some HUCB cells are positively
labeled with the antibodies against neural markers including Nestin, III BetaTubulin (TuJ1), and glial fibrillary acidic protein (GFAP) (31). Animals receiving a
high dose of HUCB cells had a significantly longer life span than animals with low
dose HUCB administration (32). Based on these promising effects of HUCB
treatment of ALS mice, the clinical trials with hematopoietic stem cells are under
way. Janson et al (33) isolated CD34+ stem/ progenitor cells from peripheral
blood, and CD34+ cells are believed to be the key stem cell component in HUCB.
The purified CD34+ cells were intrathecally injected in three ALS patients. After
6–12 months, none of the patients reported side-effects, but no clinical efficacy
was seen (33). Although the expected success was not achieved, there were at
least no harmful effects to the patients. Further, since the total cases are too few
for statistical analysis, it is too early to make a conclusion.

Sanfilippo syndrome is a genetic disease which produces a deficit in the
alpha-N-acetylglucosaminidase (Naglu) enzyme, which is critical to the break
down of the glycosaminoglycan (GAG) heparin sulfate in the lysosome. The
disease is characterized by diffuse neural and other organ degeneration, and the
patient usually dies at 11-12 years of age. Recent studies showed that HUCB
may correct this enzyme deficit, and provide a treatment for this disease. In the

8

laboratory, animals with a mutation in the Naglu gene received i.v. injections of
mononuclear cells from HUCB that had the normal Naglu enzyme on the 5th day
of pregnancy during blastocyst implantation. The HUCB cells were incorporated
into the embryo during its development, and these cells functionally corrected the
deficit in Naglu enzyme expression (34).

In addition, HUCB transplantation is a promising approach in the treatment of
Parkinson disease (35). In the experiment, HUCB was delivered into Parkinson
disease mice (B6CBACa-AW-J/A-KCNJ6) through intravenous administration.
The other animals were transplanted with bone marrow or untreated as control.
The life span of these mice was examined. When 50% of the control animals
died, only 1 out of 10 animals from bone marrow transplanted animals, and 2 out
of 12 HUCB injected animals had died. After 200 days, the control group only
had 10% of the original animals alive, and bone marrow transplanted group had
20%. Interestingly, the survival rate in the HUCB treated animals was 33%.
There were significant differences between the HUCB treated group and control
group. In addition, HUCB treated mice had less Parkinson’
s disease symptoms.
It is possible for the grafted HUCB to partially correct the deficits due to a loss of
dopamine neurons (35).

1.3 Mechanisms of Functional Recovery in Stroke
1.3.1 Cell replacement
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1.3.1.1 Characterization of neural properties of HUCB
In our research group, we routinely cultured the mononuclear fraction of
HUCB cells in DMEM with 10% FBS (36). The cultured HUCB cells apparently
separated into two different fractions: an adherent subpopulation and a floating
subpopulation. The adherent subpopulation mainly expressed CD45, and a few
cells expressed stem cell markers such as CD133 and CD117. These cells can
have a variety of morphologies; some cells are large and egg-shaped, others are
bipolar, or have multiple hair-like spines, are multipolar, or are small and round
with processes. While still floating, the cells of the floating fraction remain small
and round, exhibiting less differentiated properties. However, once these cells
were replated, they adhered to the culture dish and they differentiated and
developed long process. The expression of CD45 in the culture decreased, but
CD133 and CD 117 increased, suggesting these cells are still primitive, since
CD133 and CD117 are stem/precursor antigens.

Interestingly, even without any cytokine stimulation, some of these cells
from both the adherent and nonadherent fractions still expressed neural markers.
The adherent cells expressed Nestin, A2B5 and GFAP (Glial fibrillary acidic
protein), and even the neurotrophin receptors trkA, trkB, and trkC. The presence
of neurotrophin receptors suggests that these cells have a potential to become
neural-like cells after induction. In the floating cell fraction, all the markers
including nestin, GFAP, TuJ1, and A2B5 were found in cultured HUCB. S100,
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GalC, trkB, trkC were found to be enriched in the adherent fraction, while long
term culture of floating cells enriched nestin and TuJ1 expression (36).

Sanchez-Ramos examined HUCB differentiation in vitro (37). HUCB cells
were treated with retinoic acid (RA) + nerve growth factor (NGF), or they were
cultured in fresh DMEM + fetal calf serum (FCS). RA+ NGF treated HUCB had
heterogeneous shapes from flat epithelioid cells to small spindle-shaped cells
with branching neuritic processes, and there were fewer cells than in untreated
culture. RA+ NGF increased the proportion of the Musashi-1 positive cells up to
6.2% of the total cells, and β-tubulin III positive cells up to 18.7%, while around
1.5% cells treated with DMEM expressed Musashi-1, and 8% of cells treated
expressed β-tubulin III. Musashi-1 is a RNA binding protein in the CNS of various
species and humans (38). β-tubulin III is a specific marker of neurons, and is
believed to be involved in neuronal differentiation (39). In DMEM culture, around
34% of the total cells were immunoreactive for GFAP, a marker of astrocytes,
and this number was 66.2% in RA+NGF treated cultures (37). DNA microarray
revealed that some neural markers such as musashi-1 increased in the RA+
NGF treated group. RT-PCR found that even without treatment, HUCB had some
neural mRNA expression, which included nestin (an early neural development
marker) and necdin (a mature neuron marker). RA +NGF promoted HUCB neural
differentiation, where as musashi-1 and pleiotrophin (neurite –outgrowth
promoting protein) were only found in the RA+NGF group. This phenomena was
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more apparent in western blotting when a group of neural markers were detected
in both untreated and RA+NGF treated HUCB, and densitometric analysis
revealed more protein expressed in RA+NGF treated HUCB. These neural
markers were musashi-1, β-tubulin III, pleiotrophin and NeuN (37). These data
strongly suggested that HUCB cells can differentiate into neural cells.

It was long thought that these differentiated cells were from stem cells
within HUCB, but whether these stem cells were hematopoietic or nonhematopoietic has been debated (40). Stem cells were eliminated from HUCB
mononuclear fraction by immunomagnetic sorting with an anti-CD34+ antibody.
The remaining cells were cultured in DMEM, and the cells were replated at the
density of 10 cells/ cm2 in the presence of epidermal growth factor (EGF) once
the cells had formed a monolayer. It was found that the replated cells produced
a number of clones at the rate of about 10 times the cell number per week. The
new cells had the most primitive profile, and did not have any hematopoietic
phenotype. When stem cell depleted HUCB cells were treated with RA alone or
in combination with brain-derived neutrophic factor (BDNF), HUCB differentiated
into neural like cells, which were recognized by TuJ1, GFAP and GalC antibodies.
TuJ1 antibody recognizes neuron specific class III β-tubulin, GFAP antibody is
directed against astrocytes, and GalC is a specific marker of oligodendrocytes.
This phenomenon was also observed in HUCB co-culture with primary cortical
cells, where the markers of all three neural cell types were detected with
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immunostaining. Approximately 40% of HUCB cells differentiated into neurons,
30% differentiated into astrocytes and 11% into oligodendrocytes, suggesting the
neural environment may be critical for promoting HUCB differentiation into neural
cells (40).

The differentiation of HUCB cells was also studied in vivo (41). Freshly
thawed or cultured HUCB cells were directly administered into the striatum of
rodents, and the animals were injected with the immunosuppressive agent
cyclosporin A (CSA) or saline. Both freshly thawed and cultured HUCB were
localized within a 500-μm radius from the injection spot, and some cells even
migrated along the corpus callosum. The majority of cells displayed
hematopoietic markers including CD33, CD44, CD45, CD51/61 and CD90/Thy-1
on the surface of the injected cells. Interestingly, some of the grafted cells
exhibited neural phenotypes and were positively labeled with NeuN (a marker of
neurons), GFAP and CD11b, even though the population is not large, suggesting
these cells could differentiate into neural cells in the animal brain. Interestingly
there were no significant differences in major histocompatibility complex (MHC)
class I antigen between rats with CSA and rats without it (41). It seems the
HUCB graft caused less of an immune response, and the CSA injection was not
critical to cell survival. The possible mechanism will be discussed later in this
chapter.
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In another study, the RA+NGF pretreated HUCB was transplanted into the
anterior part of the subventricular zone of neonatal pups (1-day-old), a place well
known for neurogenesis in adult brain, and the DMEM treated HUCB was
administered as the control (42). One month later, animals were perfused, the
brain cryosectioned and immunocytochemistry was carried out to investigate the
neural phenotypes. Around 2% of the umbilical cord blood cells expressed GFAP
after transplantation, regardless of the treatment, and only less than 0.2% cells of
the total population expressed the neuronal marker β-tubulin III. These HUCBderived positive cells did not look or behave like a typical neural cells. They did
not migrate to the olfactory bulb through the rostral migratory stream, the
destination of newborn neurons in the subventricular zone. This may be because
these HUCB derived cells were highly differentiated, and did not behave like a
developing cell.

1.3.1.2 HUCB cells replace neurons after MCAO
Stroke is a cerebral vascular disease caused by a variety of insults, and
characterized by central nervous system (CNS) symptoms such as dizziness,
vomiting and even losing consciousness. Due to the neural cell loss after insult,
even with first aid and the best available care, not all of the patients can fully
recover. Currently, there are no effective treatments for this kind of disease.
Since HUCB is rich in stem cells, which could proliferate and differentiate into
neural like cells, it was thought that HUCB cells could replace the cell loss after
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transplantation.

This proposal has been examined. In one experiment, animals were
subjected to middle cerebral artery occlusion (MCAO) for 2 hours, and HUCB
was transplanted intravenously 1 or 7 days after stroke (26). The control group
was administered PBS. HUCB cells were found scattered in bone marrow,
spleen, muscle, heart, lung, and liver. Interestingly, HUCB was also found inside
the ipsilateral stroke brain, and expressed some neural markers including NeuN,
MAP-2, GFAP, and FVIII proteins as determined by immunochemistry. The
percentage of HUCB cells that expressed NeuN, MAP-2, GFAP, and FVIII
proteins was 2%, 3%, 6%, and 8%, respectively (26). In other similar
studies, HUCB recipients had much better functional recovery than the control
animals, but few HUCB cells existed in the stroked animal after intravenous
administration. Histological examination also demonstrated the HUCB graft by
itself did not reduce the infarct volume, and it only had this effect when combined
with mannitol, a reagent for hyperosmolar therapy that increases permeability of
the blood brain barrier (43). Since there are few stem cells in the HUCB, and
only a very small portion of HUCB is likely to infiltrate the stroke brain, it is hard
to imagine that these cells could fully replace the lost neurons.

1.3.1.3 HUCB induction of neurogenesis
HUCB may promote neurogenesis in the stroked animal. It has been long
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thought that neurons in the brain are highly differentiated, and cannot regenerate.
This dogma has been challenged by evidence that new neurons are born in the
“germinal zone”of the hippocampus and subventricular zone in rodents and
humans throughout life (44). Recent research demonstrated that CD34+ cells
from HUCB could enhance neurogenesis in the stroked brain after intravenous
administration (45). Animals were subjected to MCAO (middle cerebral artery
occlusion). Forty eight hours following the surgery, animals were transplanted
with CD34+ or CD34 –cells from cord blood through i.v. injection, and the cells
were pre-labeled with a fluorescent dye. Interestingly, it was found that the
transplanted CD34+ cells were not co-stained with antibody to a neuronal
(neuron-specific nuclear protein; NeuN) or astrocytic antigen (GFAP), suggesting
the transplanted cells did not differentiate into neural like cells, and it was unlikely
for these cells to replace the lost function. In addition, the enhanced endogenous
neurogenesis was observed in CD34+ recipients, but not in CD34- or PBS
transplanted animals, where newborn cells from neurogenesis were found in the
subventricular zone (SVZ) of the injured hemisphere, and they migrated to the
ischemia zone. In contrast, no newborn cells were found in the contralateral
hemisphere. These results revealed a new mechanism of action for stem cell
transplantation in stroke animals, where CD34+ cells from HUCB initially
stimulated angiogenesis and where angiogenesis further promoted neurogenesis.
The newborn cells from neurogenesis migrated into the newly restored cortex
where these cells matured and were responsible for functional recovery (45).
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The maintenance of cortical width in these animals is consistent with our
observations in the intraluminal filament middle cerebral artery (MCA) model
when dose of cells and timing of HUCB administration are optimized (27, 46).
One caveat to these results is that the migration of new daughter cells from the
anterior SVZ was limited, and the new born cells only moved a few cell diameters
after HUCB stimulation (47). It is hard for the cells to migrate long distances from
the SVZ to the destination, the infarct site, and to replace the lost tissue. While
the cortical width is greater in the HUCB treated animals, an alternate
explanation is angiogenesis and astrogliosis. HUCB contains a large number of
growth factors, including vascular endothelial growth factor (VEGF), angiopoietin1, angiopoietin-2, insulin-like growth factors (IGFs). It was well known that VEGF,
angiopoietin-1 and angiopoietin-2 are potent angiogenic factors, and CD34 cells
have the capability of expressing angiopoietin-1, angiopoietin-2. In the CNS,
although neurons and microglial cells are highly differentiated, and have limited
capability to proliferate, astrocytes also proliferate. IGF expression increased
shortly after the brain injury, and this expression was correlated to astrogliosis
(48). A similar phenomenon was observed in MS plaques (49), while IGF also
can promote angiogenesis in stroke brain (50).

1.3.2 Neurotrophic Support
HUCB may also provide trophic support to the injured brain. It is
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rich in neurotrophins, which are important for brain development and
neuroprotection. Fan et al compared neurotrophin mRNA expression in HUCB
and adult peripheral blood. They examined brain- derived neurotrophic factor
(BDNF), glial derived neurotrophic factor (GDNF), nerve growth factor (NGF) and
neurotrophin (NT). Expression of mRNA of these neurotrophins was higher in
HUCB compared to adult peripheral blood. In addition, ELISA assay revealed
that the protein expression of BDNF and NT3 in the supernatant of HUCB was
significantly higher than in adult peripheral blood (51). BDNF is a well known
neural growth factor that was first described by Barde et al (52). BDNF is
involved in the development of peripheral sensory ganglia subserving various
different modalities (53), and can decrease tissue loss in brain when
administered after hypoxic-ischemic injury in neonatal animals (54, 55).
Neurotrophin 3 (NT3) has similar effects as BDNF, and complements the trophic
effect of BDNF in the CNS (56). NGF is the prototypical neurotrophin, and NGF
protects cholinergic neurons against axotomy-induced neurodegeneration and
aged-related atrophy (57). It can prevent glutamate induced injury to neurons in
the hippocampus (58), hypoglycemia, excitotoxicity and iron-induced
degeneration (59, 60, 61) in culture.

In addition, the growth factors in HUCB cells may be effective
against the hypoxic injury caused by stroke, and improve neural cell viability. The
hematopoietic cytokine colony stimulatingfactor-1 is a growth factor in the CNS.
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It plays an important role in modulation of cell survival and/or differentiation of
neuron progenitor cells, and may play an important role in proliferation or
differentiation of neural tissue (62). IGF is another growth factor expressed by
HUCB, and it is a well known angiogenic factor. IGF is required for vessel
remodeling in CNS, and it is involved in vessel formation during brain
development (50). Recently, it has been shown that both brain-derived and
circulating IGF-I acts as a neuroprotective signals in the adult brain (63, 64). IGFI also is important for mediating the protective effects of physical exercise on the
brain (65). HUCB also expresses FGF-2, a potent neurotrophic factor in the CNS.
FGF-2 is conservatively expressed in some neurons and most astrocytes in
intact brain, and plays an important role in maintenance of neural cell function as
a local trophic factor (66). FGF-2 expression is up regulated after brain injury
(67), and stimulates tissue repair, neuron survival and axon regeneration in CNS
(68).

To determine if HUCB cells have a trophic effect when intravenously
administered after MCAO, these cells were injected 1 hour post stroke. Animals
that received HUCB and mannitol had improved functional recovery compared to
control animals, and a reduced infarct volume. In addition, the expression of
GDNF, NGF, and BDNF was significantly higher in animals that received HUCB
and mannitol compared to the control group. When HUCB cells were pretreated
with growth factor antibodies to GDNF, NGF, and BDNF, the histological and
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functional recovery was diminished in the HUCB and mannitol treated animals
(43). The author concluded that the growth factors from HUCB contributed to
functional recovery achieved by HUCB. However, peripheral blood also contains
the neurotrophins mentioned above. Why peripheral blood does not have a
significant effect on stroked brain is not clear.

1.3.3 Immune Suppression and Decreased Inflammation
HUCB grafts have a low incidence of morbidity and mortality in the
treatment of many haematological and non-haematological diseases following
high-dose myeloablative chemo-radiotherapy compared to bone marrow
transplantation (69). Clinical research demonstrated that this lower morbidity and
mortality is a result of the low incidence of graft versus host disease (GVHD) in
HUCB transplanted patients, and when GVHD does occur, it usually is less
severe (70). The GVHD is a severe inflammatory response, where T cells and
other immune effectors in HUCB attack host tissue and cause tissue damage.

Under physiological immune conditions, the naïve T cells exist in the
thymus and re-circulate through central immune organs including lymph nodes,
until they encounter antigen-presenting cells (APC), which include dendritic cells,
macrophages and B cells. For T cell immunity, dendritic cells are critical (71).
Professional APC cells absorb foreign materials and undergo antigen processing.
The processed antigen peptides are presented at the surface of APC with MHC
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(major histocompatibility complex), which include MHC Іand MHC II (72). MHC
binds TCR (T cell receptor) on the surface of T cells, and triggers T cell function.
Basically, MHC Іbinds CD8+ T cells, and matures CD8+ T cells into cytotoxic
cells; while MHC II interacts with CD4+ T cells, and CD4+ T cells become T
helper cells.

The activated T helper cells proliferate, and become either Th1 cells or
Th2 cells. Th1 cells can produce interferon-gamma (IFNγ) and tumor necrosis
factor-beta (TNF-β), while Th2 cells produce IL-4, IL-5 and IL-13. Th1 cytokine
profile favors macrophage and CD8+ cell activity, suggesting it activates the
cellular immune system. In contrast, Th2 cytokine profile stimulates B cell activity,
and promotes B cell antibody production, suggesting Th2 cells favor the humoral
immune response. Interestingly, each profile may enhance this polarization by
autocrine mechanisms, and inhibit the other pathway (73). For example, Th2
cells secret IL-4 and IL-5, which enhance the Th2 pathway, and at the same time,
Th2 cells also produce the anti-inflammatory cytokines IL-10, which inhibits the
Th1 pathway (73).

The immaturity of cord blood is exhibited on all the aspects of the immune
cascade. For antigen presentation, cord blood has impaired APC cells, especially
dendritic cells (DC), which results in less of an immune response. DC cells
develop not only from CD34+ haemotopoietic stem cells in bone marrow or cord
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blood, but also from monocytes under the stimulation of interleukin (IL)-4 and
granulocyte–macrophage colony-stimulating factor (GM-CSF) in vitro (74).
Interestingly, it was found that cord blood yielded fewer DC cells compared to
adult peripheral blood after 7 days in culture in the presence of IL-4 and GM-CSF.
In addition, the cord blood derived DC exhibited less endocytotic activity than
adult peripheral blood, characterized by less uptake of FITC-labeled particles,
suggesting DC had impaired antigen presenting ability. When these DC cells
were co-cultured with CD3+ T cells, DC cells from cord blood were not able to
activate naïve T cells as well as DCs from adult peripheral blood (75). Further,
cord blood DC cells favor the immune tolerance pathway. For example, DC cells
are classified into DC1 (myeloid DC, CD11c+, CD123-), DC2 (lymphoid DC,
CD11c− CD123 +), and iDC (less differentiated DC, CD11c− CD123-) (76, 77). The
major population of circulating DC in cord blood is of the lymphoid lineage (DC2)
and possesses an immature phenotype that favors the Th2 pathway (78, 79),
while DC1 plays a role in TH1 effector cell development (80, 81). Th2 pathway
modulates immune tolerance (80). In the cord blood, there are more lymphoid
DC2 cells than there are in adult blood, promoting the development of T cells into
Th2 cells, and down regulating the immune response (82). Further, the immature
DC produce less IL-12 than adult peripheral blood, the important effector for Th1
type activation (83), which also favors the Th2 pathway.

With respect to T cell immune function, CD4+ T cells are immature in cord
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blood. For example, CD31 is a differentiation marker on the surface of T cells,
and it is progressively and irreversibly lost during repetitive stimulation of CD4+ T
cells. There are around 10-20% CD4+ CD31- in cord blood, while this subset of
cells is undetected in adult peripheral blood, suggesting CD4+ cell are more
immature in cord blood (84). CD45 is an extracellular antigen assisting T helper
cell activation, and its length (CD45RA+) shortens following T helper cells
activation (CD45RO+). Therefore, CD45RA+ is an indicator of naïve T cells. In
one experiment, it was found that there were twice as many CD45RA+/CD45ROcells in cord blood than in adult peripheral blood. Another mature cell marker for
CD4+ cells is L-selectin (CD62L) which has been shown to indicate that the cell
is a “recent thymic emigrant”, and there were significantly fewer in cord blood
than adult peripheral blood (85). These phenomena were confirmed in another
study. CD4+CD45RA+ were collected from cord blood and adult peripheral blood,
and cultured in RPMI-1640 for 72 hours. FACS examination revealed that there
was a lower mean fluorescence intensity of CD45 on the surface of cord blood
than adult peripheral blood, suggesting an impaired T helper activation pathway.
In addition, cord blood had fewer activated CD4+CD45RA+ T cells as determined
with CD25 expression than peripheral blood. CD25 is a receptor of IL-2 located
on the surface of CD4+ cells regulating cell proliferation (86).

CD8+ cells are also immature in cord blood. In one experiment (85),
effector type cytotoxic T cells (CTL, CD8+/CD45RA+/CD27-) and “suppressor”T
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cell subsets (CD8+/CD57+/CD28-) were absent in HUCB, and there were fewer
CD8+/CD11b+ “effector”T cells in HUCB than peripheral blood. Generally, the
ratio of CD4+/CD8+ is higher in HUCB than peripheral blood, and it was
considered a HUCB indicator of blood immaturity. The deficit of CD8+ T cell
significantly impaired the function of T cells (87). In one experiment, HUCB and
peripheral blood cells were freshly prepared, or grown 5 to 7 days in culture after
collection. Cytotoxic effector cell responses were determined in a standard 4h
51

Cr-release assay. No lytic activity was detected in fresh isolated HUCB cells,

with neither NK-like lysis nor T cell lytic activity. Interestingly, after 5 to 7 days in
culture, HUCB cells developed a nonspecific cell lysis, suggesting HUCB slowly
build up the immune system. Cutaneous lymphoid antigen (CLA) is a ligand on
the surface of matured T cell, which can bind with E-selectin expressed by skin
vasculature facilitating T cell adhesion and transendothelial migration (87).
Compared to peripheral blood, CLA was absent in cord blood as demonstrated in
the above study (87).

Since CD8+ T cell function is deficient in cord blood, and the cytotoxic
pathway is retarded in response to pathogen stimulation, T cell immune response
favors the CD4+ pathway, where immune signals trigger the Th1 or Th2 cascade.
Compared to peripheral blood, HUCB exhibits an immune immature profile,
where the Th2 pathway, an anti-inflammatory response, is favored. Scientists
compared cytokine profiles in blood from HUCB, from the neonates on the 1st
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and 5th day after birth, from mothers and from controls (89). The Th1 cytokine,
IFN γ, was significantly lower in HUCB compared to adult blood, and its
concentration increased significantly from umbilical cord blood to neonates on
the 5th day after delivery. In another study (90), cord blood and adult peripheral
blood were stimulated with T-cell receptor (TCR) complex, and the expression of
cytokines IL-10, IL-4, IL-5 and IFN γ was examined. Both HUCB and adult
peripheral blood produced IFNγ, IL-4 and IL-5. IFN γis an index of Th1 cells,
while IL-4, IL-5 and IL-10 are indices of Th2 cells. Interestingly, IL-10 was
produced faster in HUCB than adult peripheral blood (90, 91), where only primary
stimulation triggered HUCB IL-10 production, while adult peripheral blood
required repeated stimulations. In addition, IL-4 and IL-12 enhanced IL-10
production in this study. The results revealed that HUCB skewed Th1/Th2 to Th2
dominance, which had anti-inflammatory effect partly through IL-10 (90).

B cells in HUCB are also immune immature. CD5 is indicative of
“primitive”B cells (92), and CD5+ B cells are also known as B1 cells, which are
associated with self-reactivity, autoimmunity, and leukemia. B1 cells produce
polyreactive IgM and natural autoantibodies but not IgG, and IgM antibody is not
sufficient in humoral immune defense. This is the reason why immune restoration
patients have more severe immunodeficiency after HUCB transplantation (93).
The percentage of B cells in HUCB is controversial, but most studies
demonstrated that HUCB had more CD5+ B cells than adult peripheral blood (87).

25

In contrast, adult peripheral blood had more mature B cells expressing
CD19+/CD23+ than HUCB, and HUCB exhibited immune immaturity with more
CD19+/CD23- B cells (84). This immaturity was also observed at the level of the
gene (94). B cells derived are from hematopoietic progenitor cells, or pro-B cells,
are designated as CD10+ CD19- CD22- CD34+. When pro-B cells develop into
B cells, the immunoglobulin heavy chain is rearranged which ensures correct IgH
secretion. Hirose compared the IgH gene of B cell subsets from pro-B cell, pre-B
cell to B cells in HUCB and in adult peripheral blood through RT- PCR (94). It
was found that pre-B cells derived from HUCB had a shorter N region than those
derived from adult peripheral blood. In addition, immunochemistry staining
revealed that a B cell differentiation related gene, the terminal deoxynucleotidyl
transferase (TdT) gene, was not detected in cells derived from HUCB. These
results indicated that the HUCB B cell lineage is immature.

Another important mononucleated population in cord blood, monocytes, is
also immature. As professional antigen presenting cells, monocytes can activate
T and B cell immunity with the stimulation of pathogen. In one experiment (95),
monocytes derived from adult peripheral blood induced burst-promoting activity
(BPA) of T cells derived from adult peripheral blood in vitro in the presence of
phytohemagglutinin (PHA). When the monocytes from adult peripheral blood
were replaced with monocytes derived from cord blood, the BPA was significantly
decreased (95). Monocytes were also unresponsive to hepatocyte growth factor
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(HGF) stimulation, a potent effector for monocyte activation in adult blood. In
one experiment, Jiang showed that HGF significantly increased the monocyte
antigen presenting capacity of adult peripheral blood, and up-regulated HLAclass I expression in adult peripheral, but did not in HUCB (96). The cytokine
profiles of HUCB monocytes were different from adult peripheral blood (97).
Monocytes derived from HUCB produced less IL-1βand TNF-αthan those
derived from adult peripheral blood, and the cells were limited in CD64+ CD14+
cells. In contrast, monocytes derived from adult peripheral blood had more cells
to secrete IL-1β and TNF-α, which include CD64+ CD14+ cells, CD64+ CD33+
cells and CD64+ CD45RO+ cells. In addition, cord blood monocytes lack CD11b,
CD11c, CD49d expression compared to adult blood, and rIFNγ stimulation lead
to the of loss of CD58 and CD102 expression in cord blood cells, and a low
intensity labeling of CD29, CD54 and CD102 compared to adult blood (98).
CD11b, CD11c, and CD49d belong to the integrin family and are very important
in platelet aggregation, inflammation, immune function, tumor metastasis, and
tissue migration (99). CD54, CD58 and CD102 are involved in controlling
receptor mediated signal-transduction, as intercellular adhesion molecules (100).
The decrease in expression of these markers reflects the low intensity of immune
response of HUCB.

This inhibited immune response was also confirmed in vivo in our lab
(101). HUCB was intravenously administrated into rodent animals following
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MCAO. Twenty four hours after delivery, the inflammatory cell population in
stroked brain was analyzed with flow cytometric analysis. HUCB recipients had
fewer CD45+/CD11b+ and CD45+/B220 cells in brain compared to MCAO only
animals, while there was no significant difference between treated and untreated
rats in the number of CD45+/CD3+ and CD45+/NT cells in the brain. In addition,
the pro-/anti- inflammatory cytokines were measured with both RNase protection
and ELISA. The pro-inflammatory cytokines TNF α, IL-1β and IL-6 significantly
increased shortly after stroke stimulation. When HUCB was administrated, the
high expression of pro-inflammatory cytokines was diminished to a similar level
as sham control. Interestingly, HUCB administration also decreased the activity
of NF-κB, which is the main transcription factor that induces TNFα expression
(102).

1.4 Do HUCB cells get into the brain?
The argument can be made that the HUCB cells do not need to get into
the brain to have their therapeutic effects. While the best effects occur with i.v as
opposed to intrastriatal delivery, some of the cells can be observed in the brain
after i.v. administration (43). Transplanted HUCB cells were observed in the
cortex, subcortex, and striatum of recipient rats (26).

Since brain is highly insulated by the blood-brain-barrier (BBB), it is
difficult for large molecules to cross this barrier. However, after the stroke, the
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BBB is damaged and blood cells in the circulatory system could leak through the
damaged blood brain barrier (BBB) into the region of the infarct. Consistent with
the passive leakage of cells into the brain is the observation that when HUCB
cells were delivered 7 days after MCAO, animals had less motor and
neurological recovery compared with the HUCB group treated 24 hour after
MCAO (103). The BBB is almost recovered at this time (104), and therefore,
fewer HUCB cells may be able to cross the BBB. Once in the brain, T cells may
recognize their antigen, triggering an inflammatory process with the subsequent
production of cytokines that could activate and/or further damage the
endothelium of the BBB, allowing the passage of the other cells. These T cells
also express chemokines (MIP-1α/CCL3, MIP-1β/CCL4) (105) and increase the
expression of the chemokines in astrocytes and perivascular macrophages (106).
In addition, stroke increases some chemokine expression in the CNS (107). This
then is a second possible mechanism. The elevated chemokines facilitate the
passage of HUCB cells into the brain.

Chemokines are small, soluble molecules known to recruit granulocytes,
macrophages, and other inflammatory cells in ischemic brain and cause an
inflammatory response. The chemokines are classified into four distinct
subfamilies according to the position and spacing of the conserved cysteins,
given the preferred names CXC, CC, C, and CXC3, also referred to as α, β, γ,
and neurotactin, respectively (108, 109). Since the first chemokine, IL-8, was
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discovered (110), more than 50 chemokines have been reported, and they
interact with at least 18 receptors. Macrophage inflammatory protein (MIP)-1α,
and monocyte chemoattractant protein-1 (MCP-1) belong to the β-chemokine
family, and have been implicated as potential modulators of lymphoid and
mononuclear cell infiltration into the CNS (111). MCP-1 is a 76 amino acid
molecule with 8-15 kD weight, and originally was identified as an immediate early
gene product induced by a platelet-derived growth factor in mouse 3T3 fibroblast
cells (112). MCP-1 has highly specific chemotactic properties for monoccytes
with little effect on leukocytes or lymphocytes (112, 113). MCP-1 expression is
prominent within the atherosclerotic lesion (114), inflamed synovium, and
glomerulus, and extensively exists in peripheral organs such as ischemic kidney,
liver and lung, and in rheumatoid arthritis (115). The level of MCP-1 is very low in
intact CNS, while stroke, HIV, and multiple sclerosis significantly increase its
production (116). MCP-1 mRNA was increased as early as 4 hours in the
ipsilateral hemisphere following ischemia, and until 5 days post stroke depending
on the animal model and examination methods (117,118), whereas the level of
MCP-1 in the contralateral hemisphere was similar to control levels. Double
staining with neuron specific antigen or glial fibrillary acidic protein (GFAP)
showed these MCP-1 positive cells were predominantly astrocytes, although
some neurons were also labeled (119). Other studies found that hypoxiaischemia results in MCP-1 expression in multiple cell types around the site of
injury in neonatal rodent brain (120). Following MCP-1 expression, leukocytes
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are found in the lesioned hippocampus. In addition, mutant mice with a CCR2
(MCP receptor) deficit had neither T cells nor macrophage infiltration in the
denervated hippocampus, suggesting a critical role for MCP-1 and its receptor
CCR2 in leukocyte migration (121).

MIP-1 is a potent chemokine, and was first isolated from supernatant of
endotoxin-stimulated murine macrophages (122). The primary isolation was
further separated and yielded two distinct but highly related proteins, MIP-1αand
MIP-1β, which share 68% identical amino acids (123). MIP-1α is produced by
many kinds of cells, such as T cells, B cells, neutrophils and macrophages, and
also has been detected in an immortalized mouse microglial cell line (124),
cortical astrocytes and monocytes (125). Stroke can increase MIP-1αexpression
at the lesion site as early as 1 hr post insult, while no changes were observed in
the contralateral hemisphere (126, 127). An in vivo study demonstrated that this
MIP-1αexpression was correlated with mononuclear cell infiltration (128). This
chemoattractive effect was further verified in vitro. Extract from ischemic brain
could induce human bone marrow stromal cell migration in interface migration
cultures, and this cell migration could be blocked by MIP-1αantibody (129).
Similar results were achieved in experiments with lymphocytes (130), and
monocytes (131) as well as other subpopulation of mononuclear cells. In addition,
accumulating evidence indicates that MIP-1αalso has various effects on the
growth of hematopoietic progenitor cells. MIP-1α is an active component of
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normal bone marrow extract that can inhibit the proliferation of multipotential
hematopoietic progenitor cells as determined with the spleen colony-forming unit
assay (132, 133). In vitro MIP-1α enhances growth of mature myeloid progenitors,
but suppresses the growth of immature ones (134, 135). It was also documented
that MIP-1αcould modulate hematopoietic progenitor cell adhesive properties
(136).

Therefore, along with the leakage through BBB, stroke would also
enhance some chemokine expression around the ischemia site, which in turn
could induce HUCB cells to migrate across the BBB after intravenous
administration.

1.5 Hypothesis
In this study, we hypothesized that MCP-1 and MIP-1expression
increases in the damaged hemisphere after stroke and facilitate HUCB cell
migration into the ischemic brain. Once inside the brain, HUCB cells could
suppress the inflammatory response, and support neuron and astrocyte survival
in the hypoxic condition. This hypothesis has been examined using in vivo and in
vitro experimental models.

1.6 Specific Aims
Aim 1. Verify the chemotactic effect of MCP-1 and MIP-1in ischemic
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brain extracts on HUCB migration in vitro.

Aim 2. Determine the effects of HUCB cells on cell survival of neurons,
astrocytes and microglia in vitro.

Aim 3. Determine if the effect of HUCB cells on neurons, astrocytes and
microglia is dependent on a specific subpopulation of HUCB cells.
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CHAPTER TWO
GENERAL MATERIALS AND METHODS

2.1 The Middle Cerebral Artery Occlusion Rat Model
2.1.1 Animal housing and maintenance
Adult Sprague Dawley rats (average body weight range: 175±25 g) were
used in this study. The animals were housed in the Vivarium in the University of
South Florida, College of Medicine. Animals had free to access to water and
food, and were maintained in a 12 hour dark/ light cycle in a temperature
controlled room for 7 days prior to surgery.

2.1.2 Surgical Procedure
The surgery was performed under the guidelines of the National Institute of
Heath as approved by the University of South Florida Institutional Animal Care
and Use committee. Animals were anesthetized with Isoflurane (2-5% in O2
delivered at 2L/min) first, and once the animals were in a deep sleep as indicated
by no response to toe pinch, the gas delivery was reduced to 1 liter/min, and the
neck skin shaved and disinfected with iodine and 70% alcohol. Using blunt
dissection, the right common carotid, external carotid, internal carotid and
pterygopalatine arteries were exposed. The common carotid artery was carefully
separated from the vagus nerve and surrounding tissues. A temporary tie was
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placed on the pterygopalatine in order to stop blood flow and prevent entry of the
embolus into this artery. The external carotid artery was tied off with two 5-0 silk
sutures and sacrificed by cutting just above the bifurcation of the internal and
external carotid arteries. The embolus was inserted through the external carotid
and guided into the internal carotid artery, past the base of the skull to the origin
of MCA, a distance of approximately 25mm. The external embolus was
permanently tied in, and the skin was sutured. Each animal was put on a
warming blanket until they recovered consciousness. The animals were returned
to their home cages until they were euthanatized 24 hours later.

2.2 Animal Sacrifice
Animals were carried to the surgery room, and the cage cover was replaced
with an air-sealed cover having a connection to a CO2 tank. Animals were
euthanized by CO2. When there was no response to stimulation, or the toe pinch,
animals were guillotined. The skulls were opened, and brains were carefully
removed with a spatula. The brains were immediately snap frozen in liquid
nitrogen and stored for future use.

2.3 Neural Cell Isolation and Culture
2.3.1 Primary Brain Cell Isolation
Pregnant Sprague Dawley rats (Harlan Sprague Dawley) were housed
with free access to food and water for 2 days. When the pups had developed to
embryonic day 17 (E17), the mother was sacrificed as described above, the
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abdomen was opened, and the pups were removed from the mother’
s belly.
The heads of pups were cut with scissors, and were placed in cold DMEM on ice.
All neural cells isolation procedures were performed on ice. The skulls were
opened with fine forceps under a dissecting microscope, and the blood vessel
and meninges of the brain were carefully removed. The brain was minced with a
scalpel in Earle's Balanced Salt Solution (EBSS) containing 20 μg/ml DNase and
0.3% Bovine Serum Albumin (solution A) on ice. Following this, the homogenate
was centrifuged at 500 xg for 2 min, and the pellet was collected and incubated
in EBSS containing 0.025% trypsin, 60 μg/ml DNase and 0.3% Bovine Serum
Albumin (solution B) at 37°C for 15 min to dissolve the connective tissue between
cells. Trypsinization was stopped with 10% fetal calf serum (FCS), and the
solution was centrifuged again at 500 ×g for 2 min. The pellet was resuspended
in solution A and triturated through a fire-polished Pasteur pipette. The solution
was allowed to settle for 4 minutes and the supernatant was collected. Then
more solution A was added to the pellet before repeating this process twice. The
collected supernatant was combined together and centrifuged at 500×g for 5 min.
The pellet with cells was resuspended in culture medium (DMEM supplemented
with 10% (v/v) FCS).

2.3.2 Neuron Enriched Cultures
Following tissue cell isolation, the isolated cells were plated at a density of
2.5×105 cells/cm2 in a flask coated with poly-L-lysine. After 3 days in culture,
medium was changed to Neurobasal (500 ml) and supplemented with 10ml 50 X
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B-27, 5 ml Antibiotic/Antimycotic, 2.5 ml glutamine, 0.5 ml 1:1000 glutamate. Ten
μM 5-fluro-2’
-deoxyuridine and 10 μM uridine were added to inhibit growth of all
other cell types except neurons. Using this procedure, 85–90% of the cells were
neurons as determined by cellular morphology.

2.3.3 Astrocytes Enriched Cultures
The isolated brain tissue cells were plated in 50 ml flask coated with polyL-lysine at the density of 2.5×105 cells/cm 2. DMEM (Gibco) with 10% FCS was
added into flask, and cells were cultured at 37o C in 5% CO2 in an incubator. The
medium was changed every two days. Since astrocytes grow faster than other
neural cells, they take over the cell culture after 5 days in vitro (DIV) with minor
neuronal and microglial contamination as determined with cellular morphology.

2.3.4 Microglia Enriched Cultures

The isolated brain tissues were cultured with DMEM (supplemented with
10% FCS) at 37°C in 5% CO2 without medium change until confluency. The
confluent culture was placed on a rotary shaker, and was agitated for 1 hour at
room temperature. The adherent microglia do not firmly stick to the wall of the
flask as astrocytes do, therefore to collect them, the microglia were floated in the
media, and the media was collected and spun down. The cell pellet was
resuspended in serum free DMEM and was plated at 100,000 cells/ml into a
polylysinated culture flask and maintained at 37°C with 5% CO2 for 1 hour. Under
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these conditions, microglia attached to the wall of the flask quickly and firmly,
while oligodendrocytes remained loosely attached. The oligodendrocytes were
easily floated from the wall of the culture dishes by gently shaking with the hand.
The medium was removed gently and fresh serum free DMEM was added to the
dishes, and the harvest procedure was repeated twice. The remaining cells on
the wall of dishes were purified microglia. The culture medium (DMEM with 10%
FBS and 0.1% gentamicin) was added, and cells cultured till use.

2.4 Hypoxia Culture
The gas–tight chamber was purchased from Billups-Rothenberg Inc (CA,
USA). The chamber was put inside the incubator and maintain at 37 oC. A “Y”
shape plastic pipe connected both the nitrogen tank and CO 2 tank with the
chamber. The gas tanks were turned on, and flow adjusted so that 5% CO2 and
95% N2 entered the incubator. Before hypoxia, the gas-tight chamber and the low
glucose color free DMEM medium (Gibco) were flushed with the mixed gas for 10
minutes to exclude any oxygen. Then the plates were washed with the flushed
medium, and replenished with this medium, and put into the gas-tight chamber.
The plates were exposed to hypoxia (5% CO2 and 95% N 2) at 37o C for 2 hour
(62). The control group was treated with the same volume of the hypoxia- treated
low glucose color free DMEM medium (Gibco) in an incubator at 37o C under
normoxic conditions for 2 hour. After that, the media were harvested. Some wells
in plates were treated with 10% paraformaldehyde for 5 minutes. The
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paraformaldehyde was washed away by PBS 3 times with 10 minutes per wash,
and the cells stored for future use.

2.5 Migration Assay
2.5.1

Migration Chemotactic Chamber
A 96-Chemotx Chamber (Neuro Probe) was used for these assays. The

chamber is a 96-well plate consisting of bottom wells that hold the samples or
chemical attractants and a top plate, which is a polycarbonate membrane with 5
m pore size and is where the cells are placed. The top plate is securely
attached to the bottom well plate creating a differential gradient.

2.5.2 Preparation of Brain Extracts
The nitrogen preserved tissue sample was weighed. The blood vessels
and meninges were removed under a dissecting microscope. Tissue samples
were placed into clear DMEM media containing 1% FBS (Fetal bovine serum),
1% Sodium pyruvate and 1% Glutmax, 0.1% gentamicin and 4 tablets protease
inhibitor cocktail (in 50 ml volume) at 150 mg/ml tissue weight, then homogenized
and centrifuged at 2000g for 20 minutes. The supernatants were collected and
filtered through syringe filters. All these operations were performed on ice, and
the tissue extract was kept at 4o C for next day use.
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2.5.3 Preparation of HUCB cells
Frozen samples of HUCB (Saneron CCEL, Inc) were thawed into 10 mL of
clear DMEM (Gibco) supplemented with 5% fetal bovine serum (Gibco),
gentamicin (50 g/mL, Sigma), 5% sodium pyruvate and 5% Glutamax, and
centrifuged for 7 minutes at 1500 rpm. The supernatant was removed and cells
were resuspended in 1 mL of the same media. The viability of all samples was
determined by the trypan blue dye exclusion method. Only cells with 70% or
above viability were used. Cells were then pipetted directly into the top well of the
migration chambers.

2.5.4 Basic Migration Assay
Tissue extracts (300L) were pipetted into the bottom wells of a 96-well plate.
Cells were directly pipetted into the top well at a concentration of 100,000 cells
per 60L and the top well plate was placed directly on top of the bottom well plate.
The migration chamber then was placed in a water-jacket incubator at 37 oC with
5% CO2 . Each sample, control and standard was performed in triplicate. At the
end of migration the top well plate was removed. The bottom plate was
centrifuged, and 200ml of media removed. The migrated cell number was
counted with a cell viability assay. Briefly, one vial of CellTiter-Glo Substrate from
this kit was melted into 10 ml CellTiter-Glo Buffer, and 100ml of the solution was
added into the plate. After 10 minutes, the plate was read in a plate reader to
determine the number of cells that had migrated into the lower chamber.

40

2.6 Western Blotting
2.6.1 Preparation of Tissue Sample
The brains in liquid nitrogen were sagitally cut into stroked side and nonstroked side. The connective tissues including vessels and meninges were
removed, the brain was minced and put into 3 volumes of lysis buffer (100.0 ml
lysis buffer contains 1.0 M Tris-HCl (pH8.0), 0.5 M EDTA, 1.0 M DTT, 1.3 M
Spermine, 3.1 M Spermidine, 50 ml Glycerol, 4 tablets protease inhibitor cocktail,
2.5 M KCL and 47.7 ml H2 O). The tissue mixture was sonicated for 1 minute, the
tissue lysates centrifuged at 10,000 g for 10 min, and the supernatants collected.

2.6.2 Gel Preparation
Tissue lysate protein concentrations were assayed (BCA Protein Assay kit,
Pierce Biotechnology, IL), and mixed with laemmli buffer (BioRad, Inc) containing
5% mercaptoethanol, and denatured at 100oC for 10 minutes. While the samples
were being denatured, 12% SDS polyacrylamide gel (Invitrogen, Inc) was loaded
on the running apparatus, and it was filled with 1X NuPage running buffer
(Invitrogen, Inc). The samples were then spun down, and the same amount of
protein was loaded on each lane of the gel; the molecular weight marker (see
blue, Invitrogen Inc) was loaded to indicate the running front. The electrophoresis
apparatus was placed in a cold room, and run at 100 V for 15 minutes, then the
voltage was switched to 60 V and run overnight.

2.6.3 Protein transfer from Gel to Nitrocellulose Membrane
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Before transfer, the nitrocellulose membrane (Invitrogen, Inc), blotting
paper, and fiber pads were soaked in 1 X NuPage transfer buffer (Invitrogen, Inc)
for 15 minutes. The gel was unloaded and the transfer “sandwich”assembled in
the sequence of fiber pad, one sheet of blotting paper, gel, nitrocellulose
membrane, one sheet of blotting paper and fiber. The “sandwich”was placed in
the transfer buffer, and the air bubbles were rolled out with a rod. The sandwich
cassette was loaded into the transferring apparatus with the nitrocellulose
membrane facing the positive anode. Then the apparatus was filled with 1 X
NuPage transfer buffer, and the blot transferred to nitrocellulose at 100V for I
hour in a cold room.

2.6.4 Antibody Incubation
After transfer, the nitrocellulose membrane was washed three times for 15
minutes in TTBS buffer containing 2.42g Tris-Base, 8.0 g NaCl, and 0.1% Tween
in one liter of distilled water. Then the membrane was blocked with 5% non-fat
milk prepared in 1X TTBS without 0.1% Tween for 1 hour. The membrane was
further washed with 1 X TTBS (3 X 5 minutes), and placed in the primary
antibody solution for incubation overnight. The antibody solution was prepared
with 25 ml TTBS and 0.1 g non fat milk, and the concentration of antibody was
adjusted accordingly. The membrane was then washed three times as described
above before incubation in horseradish peroxidase-conjugated secondary
antibody solution in 25 ml TTBS and 0.1 g nonfat milk for 1 hour. The
concentration of the antibody was adjusted accordingly. The membrane was
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washed the final three times with 1 X TTBS. The membrane was probed using
enhanced chemiluminescence dye (ECL, Amersham Pharmacia Biotech,
Piscataway, NJ) and autoradiographed.

2.7 ELISA
2.7.1 Preparation of Tissue Sample
The brain tissue in liquid nitrogen was weighed, and the connective
tissues including blood vessels and meninges removed. The tissue was put in 3
volumes of tissue lysis buffer (0.1 M Tris buffer, 0.9%, NaCL, 0.5% NP-40, 1mM
EDTA, 1% Aprotinin, 0.5 mg/L Leupeptin, 0.7mg/L, 2mM PMSF), and was
sonicated for 1 minute. The tissue lysates were centrifuged at 10,000 g for 10
min, and the supernatants were collected. All these procedures were performed
on ice.
Then tissue lysate protein concentrations were determined with a BCA Protein
Assay kit (Pierce Biotechnology, IL), and the concentration was adjusted to the
same concentration in each sample with lysis buffer.

2.7.2 Assay Protocol
ELISA was performed according to the manufacturer’
s protocol. Briefly,
the standard dilution buffer was added to the “zero”well, and the wells reserved
for chromogen blank were left empty. The standard solution was added to the
wells with 100 μl volume, and 50 μl samples from tissue extract or medium with
50 μl standard dilution buffer were added into the plates to make all the wells
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have the same volume.

Then, 50 μl of biotinyltated anti-IFN(or any other

cytokine to be tested, see Table 2.1) solution were added into each well except
the chromogen blanks. The plates were covered and incubated for 30 minutes at
room temperature. The plates were washed 4 times, and100 μl streptavidin-HRP
working solution was added to each well except the chromogen blank well.
After 45 minutes of incubation, the plates were washed 4 times, and 100 μl
stabilized chromogen from the kit was added in each well. The plate then turned
blue and it was further incubated for 30 minutes. The reaction was stopped with
the 100μl stop solution. Then the concentration of cytokines was determined on a
plate reader with light absorbance at 450nm.

Table 2.1

Parameters of ELISA assay

Cytokines

Standard Curve

Sensitivity

IL-1 β

0- 2000 pg/ml

> 3 pg/ml

IFN-γ

0 - 1400 pg/ml

> 13 pg/ml

IL-6

0 –2000 pg/ml

> 8 pg/ml

IL-10

0- 1000 pg/ml

> 5 pg/ml

2.8 Immunohistochemistry
The brains stored in 4% paraformaldehyde were transferred into 20%
sucrose (20g sucrose, 80ml H2 O) overnight, frozen, sectioned on a cryostat at a
30µm thickness, and stored in Walther’
s Antifreeze (NaH2 PO4 x1 H2 O 1.389g,
Na2HPO4 5.45g, H 2O 400 ml, Ethylene Glycol 300 ml, Glycerol 300 ml) until
44

further use. For immunohistochemistry, sections were washed three times (10
minutes each time) with 0.1 M PBS (pH.7.3). After washing, sections were
incubated with blocking solution (10% normal serum, 3% Triton X100 in 0.1M
PBS) for 1 hour, then incubated with primary antibody at 4oC overnight (see
Table 2.2). The sections were washed three times (10 minutes each time) with
0.1 M PBS (Ph7.3), then incubated with secondary antibody in blocking solution
(10% normal serum, 3% Triton X100 in 0.1M PBS) at room temperature for 1
hour. The secondary antibodies were either rhodamine-conjugated IgG or FITCconjugated IgG. The sections were mounted and examined under
epifluorescence.

Table 2.2. Antibodies used for immunohistochemical labeling of cells
Antigen

Host

Species Cross reactivity

Dilution

Source

MCP-1

Rabbit

Rat

Mouse

1:100

Novus

MIP-1α

Goat

Rat

Mouse

1:100

SANTA CRUZ

OX-42

Mouse

Rat

Not confirmed

1:100

Abcam

Tubulin

Mouse

Mouse

Human, Mouse, Rat

1:100

Chemicon

GFAP

Mouse

Rat

Human, Mouse, Rat

1:100

Chemicon

CCR5

Goat

Human

Not tested

1:200

Capralogics

CCR1

Rabbit

Human

Mouse

1:200

Abcam

CCR2

Mouse

Human

Not tested

1:200

Abcam

2.9 Magnetic Cell Sorting
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Cryo-preserved HUCB cells (Saneron CCEL Therapeutics, Inc, Tampa FL)
were freshly thawed into 10 ml PBS (PH.7.3), and centrifuged at 1000 rpm for 10
minutes. The cell pellet was resuspended in 1 ml PBS, and the cell number was
counted with trypan blue exclusion methods. PBS was refilled to 10ml, and the
cells were centrifuged again. The cell number was adjusted to 107 per 90 µl in 1X
BD Image, and HUCB cells were incubated with 10 µl anti-human CD8 magnetic
nanoparticles (BD Bioscience, cat. No. 557765), anti-human CD11b magnetic
beads (MACS, No. 130049601), or anti-human CD19 magnetic nanoparticles
(BD Bioscience, cat. No. 551521) at room temperature for 15 minutes
respectively. The cell solution was washed with 1 X BD Image buffer 20 times,
and supernatant was removed completely. The cell pullet was suspended, and
cell concentration adjusted to 2 X 107 cells/ml in cold 1 X BD Image buffer. The
labeled cell suspension was transferred to the positive-fraction collection tubes
(12 X 75mm tubes), and the positive-fraction tubes were placed into the magnetic
holder for 6 minutes. The positive labeled cells were attached to the wall of the
tube, while the negative cells sank to the bottom of the tube or floated in the
medium.

The supernatant was removed, and cell sorting repeated twice as

described above, except the cells were incubated for 2 minutes instead of 6
minutes. The positive cells were washed and collected with 1 X BD Image buffer.

2.10 Confocal microscopy
The specimen is immunolabeled as described in section 2.8. Before
confocal microscopy, the slides were examined under conventional fluorescent
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microscopy, confirm the staining, and identify candidates for confocal
microscopy. For fluorescence reporting with Alexa 488 (FITC, green), the laser
458/476/488/514 nm line is needed. For fluorescence 633, the laser 633 line is
needed. If the slides are stained with fluorescence 568, the laser 568 line is
needed.

Mount slides, and turn on the confocal microscope and computer. Choose
the laser lines of choice and filter parameters. These parameters include I3, N2.1
and Y5.

I3 is for blue excitation and green emission (FITC, Alexa 488, etc.).

N2.1 is for green excitation and red emission (Rhodamine, etc.) and Y5 is for red
excitation and long red emission (CY5, Alexa 633, etc.). Once these are set, set
the other scan-related parameters that include Mode, Scan Speed, Scan Format,
Pinhole size, Zoom factor and Image Average. The slides are then scanned and
images saved.
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CHAPTER THREE
MIP-1Α AND MCP-1 INDUCE MIGRATION OF HUMAN UMBILICAL
CORD BLOOD CELLS IN MODELS OF STROKE

3.1 Abstract
BACKGROUND AND PURPOSE: Monocyte chemoattractant protein-1 (MCP-1)
and macrophage inflammatory protein (MIP-1α) are β-chemokines, implicated in
monocyte infiltration into the central nervous system (CNS) under pathological
conditions. We previously showed that both in vivo and in vitro human umbilical
cord blood cells (HUCB) migrate toward brain injury after middle cerebral artery
occlusion (MCAO). We hypothesized that MCP-1 and MIP-1α may participate in
the recruitment of HUCB towards the injury, and investigated the possible
mechanism in culture.
METHODS: Sprague-Dawley rats were subjected to MCAO and 24 hours later
the production of MCP-1 and MIP-1α in the brain was examined with
immunohistochemistry, ELISA, or western blotting. The chemotactic effect of
MCP-1 and MIP-1αfor HUCB were evaluated with interface culture assays, and
the expression of MCP-1 receptor CCR2 and MIP-1αreceptor CCR1, CCR5 on
the surface of HUCB was also examined.
RESULTS: MCP-1 and MIP-1αexpression was increased in astrocytes, microglia
and neurons of ischemic brain. Interface culture assay revealed that the brain
48

extract from ischemic hemisphere significantly promoted HUCB cell migration
compared with the extract from the contralateral side, and this cell migration was
neutralized with polyclonal antibodies against MCP-1 or MIP-1α. Also, chemokine
receptors were constitutively expressed on the surface of HUCB cells.
CONCLUSIONS: Ischemia significantly induces MCP-1 and MIP-1αexpression
around the infarct. The up-regulated chemokines can bind cell surface receptors
on HUCB, and induce cell migration, demonstrating a mechanism for infiltration
of systemically delivered HUCB cells into the CNS in vivo.

Key Words: MCP-1, MIP-1α, MCAO, HUCB

49

3.2 Introduction
Intravenous delivery of human umbilical cord blood cells (HUCB)
decreases neural damage in rodents subjected to middle cerebral artery
occlusion (MCAO), and provides better behavioral and neurological recovery in a
rodent model of stroke compared to direct intracranial delivery (25). While an
additional advantage of the systemic route is the ease of delivery, how these
cells migrate into the brain to produce their effects is not clear, since the brain is
insulated by the blood brain barrier (BBB) and has immune privilege. One
possibility is that BBB is disrupted after the ischemic insult and granulocytes,
macrophages, and other inflammatory cells leak into the ischemic brain passively.
A second possibility is that stroke up-regulated chemoattractants, which promote
HUCB cell migration into the brain. One of the potential chemoattractants is
monocyte chemoattractant protein-1 (MCP-1). MCP-1 has been detected in
injured brain after stroke (121), predominantly in astrocytes (137). Other studies
found that hypoxia-ischemia increases MCP-1 expression in multiple cell types
around the site of injury in neonatal rodent brain (119). Following MCP-1
expression, leukocytes could be found in the lesioned hippocampus. In addition,
mutant mice with a CCR2 (MCP-1 receptor) deficit had neither T cells nor
macrophage infiltration in the denervated hippocampus, suggesting a critical role
for MCP-1 and its receptor CCR2 in leukocyte migration (121).

Another potential chemoattractant implicated in the trafficking of lymphoid
and mononuclear cell into the CNS is macrophage inflammatory protein (MIP-1α).
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It is up regulated as early as 3 to 6 hr post stroke in the ipsilateral hemisphere to
the stroke, whereas the level of MIP-1αin the contralateral hemisphere was
similar to control levels (120,127). MIP-1α mRNA was also found present in an
immortalized microglia cell line, cortical astrocytes and monocytes in culture
(125). In vivo, MIP-1αexpression was correlated with mononuclear cell infiltration
(128). Further, extracts from ischemic brain induced human bone marrow stromal
cell migration in culture, and this cell migration could be blocked by an MIP-1α
antibody, suggesting a chemoattractant effect of MIP-1α(129).

In this study we examined whether MIP-1and MCP-1 expression
increased in the damaged hemisphere after stroke and if the presence of these
chemokines in extracts of stroke brain would induce HUCB migration in an ex
vivo assay system.
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3.3 Materials and Methods
3.3.1 Middle Cerebral Artery Occlusion (MCAO)
Twenty Sprague Dawley rats were randomly assigned to the MCAO or
normal groups as previously described (25). Briefly, animals were anesthetized
with isoflurane (2-5% in 2 L/min O2 ). The right common, external and internal
carotid arteries were isolated and an embolus inserted retrogradely through the
external carotid, into the internal carotid, past the base of the skull to the origin of
the MCA (approximately 25mm from insertion). The filament was permanently
anchored in place and the incision closed. All animals were euthanized 24h post
surgery, and the brains were harvested. Some of the brains were fixed with 4%
paraformaldehyde in PBS, and the others were immediately frozen in liquid
nitrogen.
3.3.2 Neural Cell Hypoxia Culture
Neurons, astrocytes and microglia were isolated from fetal rat brain at
embryonic day (E) 17 as described (138, 139), and grown separately in culture to
confluency. Before hypoxia, the gas-tight chamber (129, 140) was flushed with
5% CO2 and 95% N2 and the plates washed with low glucose color free DMEM
medium. For the hypoxia group, medium was changed to 1 ml hypoxia pretreated low glucose color free DMEM and cultures placed in the gas-tight
chamber. The cultures were exposed to hypoxia (5% CO2 and 95%N2) at 37o C
for 2 hours (141). The control group was treated with low glucose color free
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DMEM under normoxic conditions for 2 hour. The media were harvested, and
cells prepared for western blotting.

3.3.3 Immunohistochemistry
3.3.3.1 MIP-1α(or MCP-1) double labeling. The fixed brains were sectioned on a
cryostat at 30µm thick. The sections were blocked with 10% goat serum, 0.3%
triton in PBS for 1 hour, and then incubated with primary antibody cocktail at 4o C
overnight. The cocktail consisted of goat anti MIP-1α(Santa Cruz; 1:100) or
rabbit anti MCP-1 (Novus; 1:100) with either mouse anti OX-42(CD11b/c)
(Abcam; 1:100), mouse anti TuJ1, (Chemicon; 1:400) or chicken anti GFAP
(Chemicon; 1:100). After washing, the sections were incubated with a secondary
antibody cocktail of rhodamine-conjugated goat anti-rabbit IgG (Molecular Probes;
1:500) and FITC-conjugated goat anti-mouse IgG (Molecular Probes; 1:500). The
sections were mounted and examined with a confocal microscope.

3.3.3.2 Chemokine Receptor Immunolabeling. HUCB smears were fixed with 4%
paraformaldehyde, washed and then air dried. The slides were stained with
primary and secondary antibody as described above. The primary antibody used
was goat anti-human CCR5 (Capralogics Inc, 1:200), rabbit anti- human CCR1,
and mouse anti-human CCR2 (Abcam Inc, 1:200). Secondary antibodies were
FITC-conjugated goat anti-mouse IgG or rhodamine-conjugated goat anti-rabbit
IgG (Molecular Probes; 1:500).
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3.3.4 Western Blotting
The brains were cut sagitally into stroke side (ipsilateral to MCAO) and
non-stroke side (contralateral to MCAO) and the tissue lysed. An equivalent
amount of protein was loaded on SDS-12% polyacrylamide gel and transferred to
nitrocellulose paper. The membranes were immunoblotted with anti-rat MIP-1α
(Chemicon) followed by horseradish peroxidase-conjugated secondary antibody.
After the final wash, membranes were probed using enhanced
chemiluminescence dye (ECL, Amersham Pharmacia Biotech, Piscataway, NJ)
and autoradiographed. Neural cells from culture were treated similarly.

3.3.5 MCP-1 ELISA Assay
The brains were cut sagitally into stroked side and non-stroked side.
Tissues were weighed, placed in clear DMEM (Gibco, 150mg/ml), homogenized
and centrifuged at 2000g for 20 minutes. The supernatants were collected,
filtered and adjusted to the same protein concentration. The ELISA assay was
performed according to manufacturer’
s protocol (Amersham Bioscience), and the
concentration of chemokine was determined on a plate reader at absorbance of
450nm and 550nm.

3.3.6 Cell Migration Assay
The standard (chemokine protein) or tissue extract samples (300L) with
or without MCP-1 or MIP-1antibodies (1:100) were pipetted into the bottom
wells of a 96-well plate. Freshly thawed HUCB cells were directly pipetted into
54

the top well at a concentration of 100,000 cells per 60 L. The migration
chamber was incubated at 37
C with 5% CO 2 from 4 hours to 24 hours. The top
well plate was then removed and the bottom plate was centrifuged, and 200l
media removed. The number of migrated cells was determined with CellTiter-Glo
Luminescent Cell Viability Assay, (Promega) according to the manufacturer’
s
protocol. The plate was read in a plate reader. The migration assays were
performed twice. Each sample, control and standard was performed in triplicate.

3.4 Results
3.4.1 Presence of MIP-1α and MCP-1 in the stroked brain
Both MCP-1 and MIP-1αwere found in the brain 24 hour after MCAO
using immunolabeling. No positive staining was found in the contralateral
hemisphere. Double immunochemistry staining revealed that both MCP-1 and
MIP-1αwere found in neurons (Fig 3.1), astrocytes (Fig 3.2), and some microglia
(Fig 3.3). MIP-1expression was verified with western blotting (Fig 3.4A) from
extracts of stroked brain. Further, in enriched cultures, MIP-1was expressed in
cultured astrocytes and neurons. After hypoxia, MIP-1αincreased in neurons
compared to neurons only exposed to normoxia conditions (Fig 3.4B). MCP-1
expression was verified with ELISA. It was significantly increased on the stroked
side of the brain compared to the contralateral side after stroke (p<0.05) (Fig
3.5A). In enriched cultures, hypoxia induced MCP-1 expression particularly in
microglia and astrocytes (p<0.05) (Fig 3.5 B).
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Fig. 3.1. MCP-1and MIP-1αexpression in neurons after stroke. Stroked rat
brain was immunolabelled with MCP-1 or MIP-1α(red; A, D, respectively), and
then labeled with TuJ1 (neurons; green). Both MCP-1 and MIP-1αcould be found
in neurons of the infarcted hemisphere (C, F, merged images). (G, H are
negative controls for MCP-1 and MIP-1α, respectively).
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Fig. 3.2. MCP-1and MIP-1αexpression in astrocytes after stroke. Stroked rat
brain was immunolabelled with antibodies to MCP-1 or MIP-1α (red, A, D
respectively) and GFAP (astrocytes, B, E, green). Both MCP-1 and MIP-1αcould
be found in neurons within the infarcted hemisphere (merged images C,F) (G, H
are negative controls for MCP-1 and MIP-1α, respectively).
.
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Fig. 3.3. MCP-1and MIP-1αexpression in microglia after stroke. Stroked rat
brain was immunolabelled with MCP-1 or MIP-1α(red, A, D respectively), and
then labeled for CD11b (microglia, B, E; green). Both MCP-1 and MIP-1αcould
be found in microglia of the infarcted hemisphere (merged image C,F) (G, H are
negative controls for MCP-1 and MIP-1αrespectively).
.
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A

B

Figure 3. 4. MIP-1αwestern blotting. A) MIP-1αwas present in the stroked
brain (R), and the positive control (C). L is the non-stroked side. B) MIP-1α
expression in hypoxia and normoxia cultured astrocytes, neurons and microglial
cells (HA: hypoxia astrocytes; NA: normoxia astrocytes; HN: hypoxia neurons;
NN: normoxia neurons; HM: hypoxia microglia; NM: normoxia microglia).
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Figure 3.5. MCP-1 in brain tissue and cultured neural cells. A) MCP-1
expression increased on the stroked side of the brain as shown with ELISA. B)
After enriched cultures were exposed to hypoxia, MCP-1 concentration in the
media of microglia and astrocyte cultures was significantly higher than in
neuronal medium (*, p<0.05).
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3.4.2 Chemotactic effect of MCP-1 and MIP-1α on HUCB cell migration
MIP-1αreceptors CCR1 and CCR5 as well as MCP-1 receptor CCR2
were all expressed on the cell surface of HUCB cells (Fig 3.6) suggesting that
HUCB cells could respond to expression of these chemokines. Indeed, MIP-1α
induced migration in vitro, especially at the lowest dose, 30 ng/ml (p<0.05; Fig
3.7A). HUCB cell migration to MCP-1 reached its maximum at a concentration of
600 ng/ml although this was not significantly different from the lower doses. In
contrast, the 400 ng/ml concentration was significantly different from the 30 ng/ml,
50 ng/ml and 100 ng/ml doses, respectively (* p<0.05; Fig 3.7B).

3.4.3 Effect of brain tissue extract on HUCB cell migration
Tissue extract from the stroked brain induced more HUCB cells to migrate
across a membrane than extract of the non-stroked side did (p<0.05; Fig 3.8 A).
Antibodies to both MCP-1 and MIP1-antibody depressed migration toward nonstroked values (p<0.05).

61

Figure 3. 6. MIP-1α receptors CCR1 (A), CCR5 (B) and MCP-1 receptor
CCR2 (C) were present on the surface of HUCB cells (x100).
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Figure 3.7. Chemokines dose dependently induced HUCB cell migration. A)
MIP-1at a dose of 30 ng/ml produced optimal HUCB migration after 12 hour
incubation, compared to all other MIP-1concentrations (p<0.05). B) MCP-1
dose response shows that HUCB cell migration reached its maximum at a
concentration 600 ng/ml, but owing to the variance, there was no significant
difference between this dose and the others. In contrast, the 400 ng/ml
concentration was significantly different from the 30 ng/ml, 50 ng/ml and 100
ng/ml doses, respectively (* p<0.05).
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Figure 3. 8. Effect of MCP-1 and MIP-1αon HUCB migration to brain tissue
extract. A) Extracts from the stroked side of the brain attracted more HUCB
cells compared to the non stroked side (* p<0.05), and this chemotactic effect
was significantly depressed by MCP-1 antibody; B) MIP-1αantibody also
depressed the migration of HUCB to ischemic brain extract (#, p<0.05).
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3.5 Discussion
MIP-1αwas observed on the ipsilateral injured side of the brain 24 hours
after MCAO as determined with immunohistochemistry and western blotting. Our
results are consistent with previous studies that reported MIP-1αexpression as
early as 1 hour after onset of the MCAO and which peaked at 4-6 hour post
surgery in the injured hemispheres (120, 127). MIP-1α has also been found to
increase after other brain injuries such as ischemia (142), stab wound (143),
hypoxia, olfactory target ablation (144).

The majority of MIP-1α in the body is produced by circulating monocytes.
In the CNS, the inducible MIP-1αcould exist in astrocytes, microglia, endothelia
cells or neurons. Controversy exists, with some groups finding MIP-1in the
astrocytes (127, 145) while others report that it is only produced by Mac-1
mRNA-positive cells including microglia/macrophages (142). Babcock et al (121)
observed that the MIP-1αwas expressed by glial cells and could direct
leukocytes to the CNS after axonal injury (137). Other investigators indicated
MIP-1αwas expressed by neuronal cells in culture (145). Immunostaining shows
that MIP-1αcan be in all three neural cells, but western blotting shows MIP-1α
was mainly produced by astrocytes and neurons. The inconsistency between
these studies most likely reflects differences between animal models and cell
culture techniques.
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Similar to MIP-1α, MCP-1 was also found in the ischemic brain around the
infarct. ELISA assay revealed that the amount of MCP-1 on the stroked side was
7 fold greater than the contralateral side. MCP-1 was produced by neurons,
astrocytes and microglia cells. This is consistent with previous work showing that
MCP-1 was detected as early as 3 to 6 hr post stroke in the ipsilateral
hemisphere (121) and peaked at 2 -3 days post MCAO (137). When we
examined cultures enriched for neurons, astrocytes or microglia, MCP-1 was
mainly expressed in microglia and astrocytes after hypoxia. Using
immunochemistry double staining, Che found the majority MCP-1 positive cells
were astrocytes. This is consistent with work in both cortico-striatal slice (146)
and a mouse model of ischemia (137).

However, what leads to MCP-1 and MIP-1αupregulation after stroke is not
known. Recent studies revealed that the production of MCP-1 and MIP-1α was
regulated by pro- and anti- inflammatory cytokines induced by the ischemic insult.
Interleukin (IL)-1production increased shortly after the onset of the stroke (147);
following that, MCP-1 and MIP-1α production increased. Further,
dexamethasone and IL-10 (both anti-inflammatory) significantly reduced MCP-1
expression. However, in knock out mice where interleukin-1 converting enzyme
(ICE), a cysteine protease that cleaves inactive pro-IL-1to generate mature IL1, was removed, MCP-1 expression was similar to wild type animals when
animals underwent severe hypoxia. With a less severe hypoxic incident, ICE -/did attenuate MCP-1 expression compared to wild type animals (148). The
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inductive MCP-1 expression is regulated by ligands that trigger nuclear factor
kappa B (NF-B) DNA binding. High doses of IL-6 treatment remained without
effect (149). The early expression o f IL-1βcould activate the NF-κB promoter to
induce expression. The functional NF-κB then binds the promoter of MIP-1α, and
induces MIP-1α production. When IL-1βexpression is blocked, MIP-1α
expression is inhibited (150).

The production of MCP-1 and MIP-1α could in turn elicit blood cell
migration into the brain. In a stab wound model, MIP-1αinduces T cell and
neutrophil infiltration into the brain 3 days after surgery; monocytes/
macrophages were present in the injured area 12 days post injury(143). In a
human blood-brain-barrier model, MIP-1αexpression increased shortly after
amyloid-beta stimulation, and was followed by monocyte migration from the
blood side to the brain side (151). Further, in MIP-1α knock out animals, there is
a decrease in CD8α− dendritic cell migration into the CNS after infection with
mouse hepatitis virus (MHV) (152). In addition, both MCP-1 and MIP-1αare
involved in inflammatory cell recruitment in other tissues (153, 154) after infection.
MCP-1 and MIP-1αincrease in hippocampus after entorhinodentate lesions prior
to T cell and macrophage migration into the denervated hippocampus. When
CCR2 (MCP-1 receptor) knocked out animals were used, the cell migration was
quenched, demonstrating a critical role for the CCR2 ligand MCP-1/CCL2 in
leukocyte migration. Cellular infiltration was not altered by a mutation to the
CCR5 receptor to which MIP-1α and RANTES/CCL5 bind (137). The deletion of
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MCP-1 may also result in up-regulation of other cytokines (155), suggesting a
key role of MCP-1 in a cytokine network.

These findings suggested that MCP-1 and MIP-1αmay be responsible for
HUCB cell infiltration into the CNS after intravenous administration in stroked
animals. However, it can be argued that a large enough difference in species
homology could result in no HUCB response to rodent chemokine signals. This is
unlikely since our interface migration system did induce HUCB migration, and
exhibited a dose effect. This could be due to the conservation of both MCP-1 and
MIP-1αligands and their receptors across species (156,157). In addition, we
found constitutive expression of MCP-1 and MIP-1αreceptors on HUCB.

In conclusion, we hypothesize that HUCB migration after ischemia begins
with IL-1βsecretion at the injury site, which initiates MCP-1 and MIP-1αsecretion
in activated astrocytes, microglia and some neurons. The accumulated MCP-1
and MIP-1αform a concentration gradient and when combined with the receptor
at the surface of HUCB cells, induce migration of systemically administrated
HUCB cells.
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CHAPTER FOUR
HUMAN UMBILICAL CORD BLOOD CELLS DEPRESS THE RAT
MICROGLIAL INFLAMMATORY RESPONSES IN VITRO

4.1 Abstract:
BACKGROUND AND PURPOSE: Systemic administration of Human Umbilical
Cord Blood (HUCB) cells improves behavioral and neurological recovery in the
middle cerebral artery occlusion (MCAO) model of stroke. Further, animals
receiving HUCB cells have a less severe inflammatory response compared to
MCAO only animals. However, the underlying mechanism is not clear. We
proposed that the functional recovery is due to the decreased microglial
inflammatory response in HUCB transplanted animals.
METHODS: In this study, primary cultures enriched for microglia were exposed
to hypoxic or normoxic conditions either with or without HUCB cells and
fluorescein diacetate/ propidium iodide (FDA/PI) labeling was used to determine
cell viability. The cytokine expression was examined by ELISA.
RESULTS: FDA/PI staining revealed an increase in cell death in the microglia
HUCB cell co-culture after hypoxia exposure compared to all other groups.
Accompanying the increased cell death, the concentration of IL-1βin the hypoxia
exposed co-culture medium significantly increased in comparison to the hypoxia
exposed mono-cultured group. Hypoxia also increased the expression of the pro69

inflammatory cytokine IFNγ (p<0.05), while the production of anti-inflammatory
IL-10 was inhibited.
CONCLUSIONS: Our data suggest that HUCB cells depressed the inflammatory
response after MCAO by directly affecting microglial activity. This was consistent
with our in vivo observations of decreased infiltration or activation of
microglial/macrophage like populations in the brains of HUCB treated stroked
rats, which may have contributed to their recovery.

Key word: Human umbilical cord blood, microglia, inflammatory inhibition
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4.2 Introduction
The intact brain is an immune privileged island secured by the bloodbrain-barrier (BBB). Within the central nervous system (CNS), there are no
professional antigen presenting cells, and there are few cells expressing major
histocompatibility complex (MHC) class I and II molecules (158). However, this
immune privilege could be disrupted by stroke. Microglia become activated, and
expresses MHC antigens and co-stimulatory molecules (159). The activated
microglia can acquire a phagocytic phenotype to clear neural necrosis and debris
(160). Microglia also secrete cytotoxic cytokines, free radicals and nitric oxide,
and disrupts the BBB (161). In addition, microglia can secrete chemokines to
recruit leukocytes from the circulatory system, which in turn participate in the
neuroinflammatory response.

Among the secreted cytokines, IFNγ, IL-1β, and IL-10 are of particular
interest. IFNγ was increased in stroked brain following MCAO in rodents (162),
and microinjection of IFNγ/LPS into the rat hippocampus caused a delayed
neuronal apoptosis in the hippocampus which peaked 7 days after administration
(163). When IFNγ was knocked out in the Downs syndrome mouse, neurons
had improved growth and viability (164). In addition, IFNγ can also affect
microglial vulnerability by promoting their death under stressful conditions (165).
Similar to IFNγ, IL-1β is also expressed shortly after focal cerebral ischemia. It
exacerbates the infarct volume after ischemia in rodents (166), while inhibition of
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IL-1βexpression can prevent neuronal necrosis or apoptosis caused by injury
(166). IL-1βalso can mediate microglial activation and proliferation (167). In
contrast to IFNγ and IL-1β, IL-10 is an anti-inflammatory cytokine (168). It
suppresses most of the pro-inflammatory cytokines produced in glial cells(169,
170). Changes in the balance between pro- and anti-inflammatory cytokines may
affect microglia proliferation and activity.

Our previous research has shown that systemic administration of human
umbilical cord blood (HUCB) produced better neural behavioral recovery than
control animals after middle cerebral artery occlusion (MCAO) in rodents (25).
Since HUCB is rich in progenitor cells (1), it was thought that this functional
recovery could be attributed to differentiation of the transplanted cells and
replacement of lost cells. However, immunohistological examination found that
few infused HUCB cells survived, and among them only few cells expressed
neural markers. It is unlikely that these cells proliferate and differentiate enough
to replace the cell loss caused by stroke. Interestingly, HUCB infused animals
exhibited anti-inflammatory properties with a decreased infiltration of
CD45/CD11b-positive (+) and CD45/B220+ cells into the brain. The changes
were accompanied by decreased expression of some pro-inflammatory cytokines,
decreased nuclear factor kappaB (NF-kappaB) DNA binding activity, and
increased expression of anti-inflammatory cytokines (171). Therefore, the
functional recovery of the HUCB treated rats could be the result of the
suppressed inflammatory response.
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Therefore, we proposed that the HUCB cells induced neuroinflammatory
suppression by modulating microglial activity and related cytokine expression. In
this study, a simulated ischemia / hypoxia model was used. Primary microglia
were isolated from embryonic day (E) 17 rat pups and co-cultured with HUCB
cells in culture. The cell viability as well as the cytokine expression were
examined and discussed.

4.3 Material and Methods

4.3.1 Isolation of Microglia cells
Microglia were isolated from fetal rat brain at E17 according to the
procedure described elsewhere (138). The brain was minced in Earle's Balanced
Salt Solution (EBSS) containing 20 μg/ml DNase and 0.3% Bovine Serum
Albumin (solution A) on ice. Following this, the homogenate was centrifuged at
500g for 2 min, and the pellet was collected and incubated in EBSS containing
0.025% trypsin, 60 μg/ml DNase and 0.3% Bovine Serum Albumin (solution B) at
37°C for 15 min to dissolve the connective tissue between cells. Trypsinization
was stopped with 10% fetal calf serum (FCS), and the solution was centrifuged
again at 500g for 2 min. The pellet was resuspended in solution A and triturated
through a fire-polished Pasteur pipette. The solution was allowed to settle for 4
minutes and the supernatant was collected. Then more solution A was added to
the pellet and the process repeated twice. The collected supernatant was
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combined together and centrifuged at 500g for 5 min. The pellet with cells was
resuspended in culture medium (DMEM supplemented with 10% (v/v) FCS) and
plated at a density of 2.5×105 cells/cm2 in a flask coated with poly-L-lysine.
Isolated cells were cultured at 37°C with 5% CO2 without medium change for 5
days. After medium change, cells were maintained in culture until thye had grown
to confluency. The confluent culture was placed on a rotary shaker and agitated
for 1 hour at 37°C. The media was collected and spun down. The cells were
resuspended in serum free DMEM and plated at 100,000 cells/ml into culture
flasks and maintained at 37°C with 5% CO2 for 1 hour. Loosely adherent
oligodendrocytes were floated from the wall of the culture dishes by gently
shaking with the hand. The medium was sucked off gently and more serum free
DMEM was added to the dishes. This procedure was repeated twice. The
remaining adherent cells were purified microglia. The resulting cells were
cultured with medium (DMEM with 10% FBS and 0.1% gentamicin) until use.

4.3.2 Cell Culture and Hypoxia Treatment
Microglia cells were grouped into hypoxia mono-culture, hypoxia coculture, normoxia mono-culture and normoxia co-culture. Before hypoxia, the
gas-tight chamber (129, 140) as well as the low glucose color free DMEM
medium was flushed with 5% CO2 and 95% N2 for 10 minutes. Then all plates
were washed, and refilled to 1 ml with the pre-treated medium. For co-culture, an
insert was set into the microglial plate, and freshly thawed HUCB cells were
directly pipetted into the inserts at a concentration of 500,000 cells/well. The 0.4
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μm millipore (Millipore Inc) membrane allows medium to flow freely in/out, while
the cells are held in the insert. Hypoxia groups were exposed to hypoxia (5%
CO2 and 95%N2 ) at 37oC for 2 hour, while the normoxia groups were treated
similarly under normoxic conditions for 2 hour. After that, the media were
harvested for further use. As controls, the same amount of freshly thawed HUCB
cells were directly pipetted into the same treated wells except no pre-cultured
microglia, and the HUCB cells were exposed to hypoxia or normoxia as
described above. After 2 hours culture, the media were collected and stored at 80
C until use.

4.3.3 FDA/PI Staining
Cell viability was determined by Fluorescein Diacetate /Propidium Ioidide
(FDA/PI) staining. Briefly, FDA stock solution (5mg/ml in acetone) and PI stock
solution (1 mg in 50ml PBS) were prepared and stored at 4°C. FDA working
solution (5 μl FDA stock solution in 1 ml PBS) was prepared freshly before use,
and 100 μl FDA working solution was added to the 30 μl PI stock solution as
FDA/PI working solution. Then 30 μl FDA/PI was added into each well
containing 600 μl PBS, and cells were incubated at room temperature for 5
minutes. For HUCB cells on the membranes of the inserts, the insert was
transferred into another well containing 600 μl PBS, and 30 μl FDA/PI was added
into each well. Photomicrographs were taken under epifluorescence from five
fields of each sample, which includes the center, left, right, up and down, and the
number of live (FDA labeled) or dead (PI labeled) cells were counted using
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Image ProPlus software. The experiment was repeated in triplicate. The viability
was determined as mean ±sem percentage of live cells. These data were then
analyzed using Student’
s t tests.

4.3.4 Cytokine ELISA Assay
The ELISA was performed according to the manufacturer’
s protocol
(Amersham Bioscience). Briefly, the standard dilution buffer was added to the
“zero”well, and the wells reserved for chromogen blank were left empty. The
standard solution was added to the wells with 100 μl volume, and 50 μl of media
sample with 50 μl standard dilution buffer were added into the plates to make all
the wells have the same volume. Then, 50 μl of biotinylated anti- IFN γ(or any
other cytokine to be tested, see Table 4.1) solution were added into each well
except the chromogen blanks. The plates were covered and incubated for 30
minutes at room temperature. The plates were washed 4 times, and 100 μl
streptavidin-HRP working solution was added to each well except the chromogen
blank well. After 45 minutes of incubation, the plates were washed 4 times, and
100 μl stabilized chromogen from the kit was added in each well. The plate then
turned blue and it was further incubated for 30 minutes. The reaction was
stopped with 100μl of the Stop solution. Then the concentration of cytokines was
determined on a plate reader with light absorbance at 450nm. For each condition,
there were 6 samples, and each sample was examined in triplicate. The data are
expressed as mean + sem concentration in pg/ml and were analyzed using
Student’
s t tests.
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Table 4.1. Parameters of ELISA assay
Cytokines

Standard Curve

Sensitivity

IL-1 β

0- 2000 pg/ml

> 3 pg/ml

IFN γ

0 - 1400 pg/ml

> 13 pg/ml

IL-10

0- 1000 pg/ml

> 5 pg/ml

4.4 Results:
4.4. 1. Microglial cell viability
Cell viability was determined with FDA/PI. Living (FDA labeled, green) and
dead (PI labeled, red) cells were observed in all culture conditions (Fig 4.1 A).
Cell counting revealed that under hypoxic conditions, microglia cultured with
HUCB had a lower cell viability compared to other groups (Fig4.1 B, p<0.05),
whereas there was no significant difference in cell viability between co-cultured
and mono cultured groups in normoxic conditions.
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Fig 4.1. Microglial cell viability. A. FDA/PI staining in microglia (x20). Live (FDA
labeled) cells were in green, while PI labeled dead cells were in red. B. More
microglia cells died in the co-culture condition after hypoxia exposure compared
to all other groups (* p<0.05)

4.4. 2. HUCB cell viability
HUCB cell viability was determined by FDA/PI. Living (FDA labeled, green)
and dead (PI labeled, red) cells were observed in all culture conditions (Fig4.2 A).
Cell counting shows there was no significant difference in HUCB cell viability
between all groups (Fig 4.2 B).
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Fig 4.2. HUCB cell viability. A. FDA/PI staining in HUCB (x20). Live (FDA
labeled) cells were green, while PI labeled dead cells were in red. B. There was
no significant difference of cell viability between groups.

4.4. 3. IFNγ in microglia media
IFNγgamma in the conditioned microglia media was examined with ELISA.
Hypoxia exposure decreased IFN γin cell culture medium compared to normoxic
conditions, and the level of IFN γin microglial medium cultured with HUCB had a
tendency to be higher than mono cultured microglia under hypoxic conditions
(Fig4.3). The level of IFN γin hypoxic mono cultured microglia was significantly
lower than all normoxic groups (Fig 4.3, *. # p<0.05). There was no significant
difference between the normoxic groups.
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Fig 4.3. IFN γ concentration in microglial cultures. There was significantly
less IFN γin the hypoxic mono-cultures compared to both the normoxic monocultures and normoxic co-cultures, respectively (*, # p<0.05). Interestingly, even
though there was a tendency for the hypoxic co-culture medium to have more
IFN γ expression than hypoxic mono-culture medium, there was no significant
difference between hypoxia HUCB co-culture and other groups.

4.4. 4. IL-1βin microglia media
Hypoxia exposure significantly increased IL-1β concentration in media
from mono-cultured microglia compared to all groups (*p<0.05). Hypoxia also
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increased IL-1βin the co-cultured microglia compared to normoxic co-cultured
microglia, but the concentration was at the similar level as the normoxic monocultured microglia. Interestingly, HUCB cells decreased IL-1β concentration
compared to the corresponding mono- cultured microglia in both hypoxia or
normoxia conditions. There was a significant difference between co-cultured and
mono-cultured microglia under normoxic conditions (Fig 4.4, #, p<0.05).
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Fig 4.4. Microglial IL-1 beta expression. IL-1βconcentration significantly
increased in hypoxia exposed mono-cultures compared to its normoxic monoculture group (##, p<0.05), and a similar increase of IL-1β was observed in
hypoxia exposed co-cultures compared to normoxia exposed co-culture (**,
p<0.05). In addition, there was a significant difference of IL-1β concentration
between mono-cultured and co-cultured groups under hypoxia (* p<0.05), and
this difference existed between normoxic groups (# p<0.05).
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4.4. 5. IL-10 in microglia media
IL-10 concentrations were similar in the normoxic mono-cultures and cocultures, and did not change in the hypoxic exposed mono-culture. However, in
the HUCB microglia co-culture exposed to hypoxia, there was a significant
decrease in the IL-10 concentration (Fig 4.5, *, p <0.05).
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Fig 4.5. Microglial IL-10 expression. There was no significant difference
between mono-cultured and co-cultured microglia under normoxia condition, and
the concentration of IL-10 in the hypoxia exposed mono-culture was at the same
level of these two normoxic groups. There was a significant difference in IL-10
concentration between the hypoxia exposed mono-culture group and the HUCB
microglia co-culture group exposed to hypoxia (p<0.05).
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4.4. 6. IFNγ, IL-1β, and IL-10 in cord blood media
IFNγ, IL-1β and IL-10 were undetected in all HUCB alone media, including
normoxic cultured HUCB media and hypoxic cultured HUCB media
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4.5 Discussion
This is the first study to explore the cross talk between microglia and cord
blood in vitro under hypoxic conditions. It was found the HUCB themselves were
tolerant to hypoxic conditions. When we examined the effect of HUCB on
microglia, under normoxic conditions the HUCB had no effect on cell viability of
the microglia. In contrast, HUCB cells significantly promoted microglial cell death
under hypoxic conditions, even though hypoxia alone had no effect on microglial
viability. This may explain the depressed immune response observed in our
previous studies (171). However, the mechanism underlying these observations
is not as clear.

Hypoxia decreased the concentration of IFNγin all conditioned media
compared to normoxic groups, although it had less effect on co-cultured
microglia than mono-cultured microglia. As a pro-inflammatory cytokine, IFNγis
predominantly produced by T lymphocytes and natural killer cells. It is also
produced by astrocytes and microglial cells in the central nervous system (172,
173). The concentration is usually low under physiological conditions. However,
stroke significantly increases IFNγexpression in the ischemic hemisphere (162),
and exogenous administration exacerbates the ischemia- induced brain damage
(174). In multiple sclerosis, IFNγis a major disease promoting cytokine, and
systemic administration of IFNγ worsens the disease in MS patients (175). This
adverse effect is extensive, and not just limited to neurons. It could induce
oligodendrocyte death by apoptosis as shown in vitro (176). In another study,
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pretreating microglia with IFN γincreased microglial vulnerability to FasL
mediated cytotoxicity (165), while antioxidants could neutralize the adverse effect
of FasL. It suggested that free radicals were involved in this process.

Cord blood is rich in T cells. It is possible that the IFN γwas from cord
blood. However, IFN γ was undetectable in all conditions of the HUCB alone
cultures as we observed in this study, suggesting that IFNγ originated from the
microglia, but it does not exclude the possibility that the production of IFN γmay
have been mediated by cord blood. Cord blood cells are specially adapted to low
oxygen tensions and may therefore be resistant to oxygen deprivation. In
contrast, normoxia and especially hyperoxia activate leukocytes and increase
cytokines expression (177). The change in cytokine production reflects the signal
exchange among cord blood cells through the medium, which may further affect
microglial IFNγproduction. This may be the reason for the low IFN γ
concentration in all hypoxic groups, and relatively higher concentration in
normoxia. Under hypoxic conditions, the tendency for higher concentrations of
IFN γ in co-culture medium compared to the mono-cultures may intoxicate the
microglia, leading to microglial cell death.

In the microglia mono-culutres, hypoxia stimulated secretion of the proinflammatory cytokine, IL-1β while IL-1βproduction in the hypoxic co-culture
group was not significantly different from normoxic mono-cultured microglia. IL1β is a pro-inflammatory cytokine belonging to the Th1 immune response, and is
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cytotoxic to neural cells. IL-1βis a mature product of cytokine IL-1αinteraction
with IL-1 converting enzyme (ICE), and is secreted from cells (178). IL-1β
combines with its receptor to play a pivotal role in regulation of the inflammatory
response in the CNS. It can recruit leukocytes into the CNS from peripheral blood
vessels, mediate the release of free radicals, protease, glutamate and
inflammatory cytokines from glial cells (179), and increases instantly after
stressor stimulation. The early increase in IL-1βexpression in response to
ischemia/reperfusion suggests that IL-1βis the cause of brain damage rather
than a consequence (180). Further, intracranial ventricular administration of IL1β increases the infarct size caused by ischemia, while applying IL-1 receptor
antagonist (IL-1Ra) or blocking conversion of IL-1α to IL-1βin mice with mutant
ICE have been shown to reduce neuronal damage after focal cerebral ischemia
in rodents (166). Interestingly, this IL-1β toxic effect only affects neurons in the
CNS, and is not associated with microglial cell death. For instance, in IL-1β
knock-out mice, microglia had a similar cell death profile as wild-type microglia in
response to LPS and ATP (181). In addition, IL-1βeven acted as a pluritoptent
growth factor for glial cells (182). When infused into the brain, IL-1βstimulates
astrogliosis and neovascularization at the site of injury (183), and promotes
oligodendrocyte proliferation and remyelination after CNS injury (184). In vitro, IL1β can promote microglial proliferation after N-methyl-d-asparate (NMDA)
exposure. When IL-1βproduction was inhibited, microglial recovery was retarded
and there was a decrease in DNA replication (167). Our study demonstrated that
hypoxia does activate and increase IL-1βexpression in mono-cultured microglia,
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which was consistent with previous work (185). This induced IL-1β may work as
a neurotrophic factor to prevent hypoxia- induced microglial cell death. When
HUCB cells were co-cultured with microglia, there was a decrease in the hypoxia
induced IL-1βrelease compared with monoculture, which could lead to a
decrease in hypoxic resistence, leading to cell death compared to hypoxic coculture. In this study, no IL-1β was observed in medium from HUCB alone
cultures, therefore the IL-1β was from microglial cells. In addition, a suppressed
IL-1β production was observed in the co-cultured normoxia condition in this study.
Since no toxic factors were present during normoxia, the low level of IL-1βhad
no effect on cell viability.

In contrast to the pro-inflammatory cytokines, IL-10 is an anti-inflammatory
cytokine produced by a variety of cell types including type 2 helper T cells, B
cells, macrophages, and microglial cells (168). IL-10 has neuroprotective
properites against glutamate induced neuron and oligodentrocyte death (186),
hypoxia-ischemia (187), LPS, and interferon (188). IL-10 can counteract the toxic
effect of endotoxin during hypoxia-ischemia in the perinatal brain (189). IL-10 can
inhibit nitric oxide production and nitric oxide synthase activity in murine
macrophages, and blocks the ability of macrophages to act as antigen-presenting
cells (168), which results in enhanced anti-inflammatory action. In addtion, IL-10
can directly suppress both production of pro-inflammatory cytokines and
expression of cytokine receptors in microglia (169, 170). For instance, IL-10 can
inhibit expression of the inflammatory cytokine IL-6 in vitro (190). IL-6 can induce
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anorexia (191), fever (192) and hyperalgesia (193), and its suppression reduces
the brain inflammatory response caused by kainic acid (194). Therefore, our
observed decrease in production of IL-10 in co-cultures of microglia with HUCB,
may have reduced the microglial resistance to the detrimental effect of hypoxia in
our study.

However, how HUCB cells modulate cytokine expression is still unclear.
Human umbilical cord blood cells may be immune tolerant cells and produce less
cytokines when stimulated. Han et al compared the inflammatory cytokine
production in cord blood with adult blood following stimulation with Phorbol
myristate acetate PMA, Ionomycin and Phytohaemagglutinin (PHA)/IL12. The
production of a cytotoxic cytokine profiles (IL-1α, IL-1β, IL-12, TNFα) was
significantly less in cord blood compared with adult blood (195). In another
experiment, cord blood cells were exposed to LPS, and it was found that they
had a similar cytokine expression profile as reported in Han’
s work (196). Cord
blood cells had less TNF-αand more IL-8 expression compared to adult cells
(53). Further studies revealed cord blood cells contain a large number of
immature T cells, and has few antigen presenting cells (197). However, the
current knowledge is still not enough to elucidate why cytokine production in cord
blood cells after stimulation is less than in the adult. The gene profile of cord
blood cells and the activation of signaling pathways in response to inflammatory
stimuli require further study.
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Therefore, HUCB cells may promote microglial cell death by modulating
the pro- / anti- inflammatory cytokine expression after hypoxia ischemia exposure.
The increased microglial loss after culture with HUCB cells during hypoxia
ischemia exposure further diminished the pro-inflammatory cytokine, IL-1β,
production, leading to lessened inflammation. HUCB cells may have a similar
role in vivo; systemically delivered HUCB cells could depress the inflammatory
response after MCAO by directly interacting with and destroying activated
microglia, which in turn may promote better recovery after stroke.
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CHAPTER FIVE
HUMAN UMBILICAL CORD BLOOD CELLS ENHANCE NEURON AND
ASTROCYTE SURVIVAL IN HYPOXIA CULTURE

5.1 Abstract:
BACKGROUND AND PURPOSE: Human umbilical cord blood (HUCB) cells
attenuated the neurological and functional deficits in stroked animals after
intravenous transplantation, and this functional recovery did not require HUCB
cell survival in the injured area. This phenomenon decreased the likelihood that a
-*/direct interaction between HUCB and neural cells is necessary. In contrast,
some soluble molecules could infuse into the injured brain from the peripheral
blood and play protective functions. Therefore, some small molecules, such as
inflammatory cytokines, may be involved in the functional recovery.
METHODS: In this study, the pro-inflammatory/anti-inflammatory cytokines were
examined. A neuronal cell line and primary astrocytes from E17 rats were
cultured alone or with HUCB cells in normoxic and hypoxic conditions. The
conditioned medium was collected and cytokine expression including IFNγ, IL-1β,
IL-6 and IL-10 was examined with ELISA, and cell viability was investigated with
FDA/PI staining.
RESULTS: The data revealed that HUCB cells significantly improved neuron and
astrocyte viability under hypoxic conditions. No IL-1 βor IFN γwere detected in
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astrocyte or neuronal medium. While IL-6 was not observed in cultured neuron
medium, IL-6 was only detected in hypoxia co-cultured astrocyte and normoxia
cultured astrocyte, and the concentration in hypoxia co-cultured astrocyte
medium was significantly lower than it was in the normoxia cultured astrocyte
medium. Interestingly, the anti-inflammatory cytokine IL-10 was higher in
hypoxia exposed HUCB co-cultured conditions compared to neuron and
astrocytes mono-cultures.
CONCLUSIONS: These data suggested HUCB may modulate the pro-/antiinflammatory cytokine expression, which in turn may protect neurons and
astrocytes from hypoxia induced cell death.

Key Word: Human umbilical cord blood, Neuron, Astrocytes, IFN gamma, IL-10
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5.2 Introduction
The brain is one of the most complicated networks in nature. Yet, neurons,
which compose these networks, are the most vulnerable cells in the brain. Five
minutes of hypoxia can result in irreversible damage. Unlike neurons, astrocytes
are more resistant to hypoxia, and their fates are determined by the degree and
duration of ischemia (198). Astrocytes are dispersed throughout the brain but are
positioned between the blood vessels and neurons and function as
communicators. Ischemia/ stroke can cause astrocyte activation and gliosis,
which acts to protect the neurons. For example, activated astrocytes can balance
the fluid movements between the intracellular and extracellular space, and have
the ability to take up glutamate to reduce excitotoxicity, and buffer ionic
movements (198). In addition, astrocytes can release trophic factors, which in
turn promote blood-brain barrier regeneration (199). When astrocyte supportive
growth factor-- glial fibrillary acidic protein (GFAP) is mutant, astrogliosis is
blocked, and blood-brain barrier reconstruction is retarded in animal (200).
Therefore, to promote functional recovery and enhance neuron survival,
astrocyte should be the fundamental therapeutic strategy after stroke injury.

Previous studies have demonstrated that human umbilical cord blood
(HUCB) cells have neural protective effects, and HUCB transplantation could
ameliorate the functional and cognitive deficit in stroke animals following middle
cerebral artery occlusion (MCAO) (25). However, the mechanism was not clear.
Further studies indicated that the neural protective effect could be achieved even
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without the HUCB cells taking up residence in the central nerve system (CNS),
suggesting some small molecules may cross the blood-brain barrier and induce
neuroprotection. Molecules of interest are some pro-/anti- inflammatory
cytokines.

IL-1βexpression at the mRNA level is elevated within minutes and at the
protein level within hours in response to stroke (201). Its deleterious effect on
brain is highly relevant to ischemia/reperfusion. Inhibition of IL-1 with the
exogenous antagonist IL-ra, which is believed to block all actions of IL-1 and
exert no other actions, markedly and reproducibly reduces neural loss caused by
cerebral ischemia, brain trauma, or infusion of neurotoxins in rodent (202). While
exogenous IL-1 could exacerbate the severity of the injury (203), another proinflammatory cytokine interferon gamma (IFN γ) may have a similar function. IFN
γis not normally present in the brain parenchyma, but at stress conditions, it can
be produced by infiltrating T cells and NK cells (204). IFN γ probably has no
direct effect on neural injury following ischemia, but it could elevate neural
sensitivity to deleterious factors (174). In addition, IFN γenhances the
expression of inducible nitric oxide synthase, cyclooxygenase-2, and oxygen free
radicals, which are potential cytotoxins to ischemic brain (205).

In contrast, IL-10 plays a neural protective role in ischemic brain. IL-10
can suppress production of pro-inflammatory cytokine including IL-1β, IL-6, IFN γ
and TNF α, while it also enhances IL-1ra, the natural antagonist of IL-1 β (206).
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Exogenous pre-treatment with IL-10 decreased the infarct volume in stroke
animals (207), while nullification of IL-10 expression in IL-10 knock out mice
exacerbated the damage following middle cerebral artery occlusion (208).

Thus, we hypothesized that the better behavioral score after HUCB
systemic administration could be a function of HUCB cell induced neural and
astrocytic protection, which was achieved by changes in pro-/anti-inflammatory
cytokines expression.

5.3 Material and Methods
5.3.1 Cell Preparation

Rat embryonic cerebrocortical neuronal cells were purchased from
Celprogen Inc (Cat# 12030-01), and cultured in the medium provide by the same
company according to their protocols.

Astrocytes were isolated from fetal rat brain at E17(138). The brain was
minced in Earle's Balanced Salt Solution (EBSS) containing 20 μg/ml DNase and
0.3% Bovine Serum Albumin (solution A) on ice. Following this, the homogenate
was centrifuged at 500 g for 2 min, and the pellet collected and incubated in
EBSS containing 0.025% trypsin, 60 μg/ml DNase and 0.3% Bovine Serum
Albumin (solution B) at 37°C for 15 min to dissolve the connective tissue between
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cells. Trypsinization was stopped with 10% fetal calf serum (FCS), and the
solution was centrifuged again at 500g for 2 min. The pellet was resuspended in
solution A and triturated through a fire-polished Pasteur pipette. The solution was
allowed to settle for 4 minutes and the supernatant was collected. Then more
solution A was added to pellet and the process repeated twice. The collected
supernatant was combined and centrifuged at 500g for 5 min. The pellet with
cells was resuspended in culture medium (DMEM supplemented with 10% (v/v)
FCS) and plated at a density of 2.5×105 cells/cm 2 in a flask coated with poly-Llysine. Isolated cells were cultured at 37°C with 5% CO2 and the medium
changed on day 2 and day 4 in vitro (DIV), and the cells were subcultured on 7
DIV grown to confluency. Since neurons and microglia do not flourish under
these culture conditions, the majority of the cells were astrocytes, which was
confirmed by cellular morphology.
5.3.2 Cell Culture and Hypoxia Treatment

Neurons (astrocytes) were grouped into hypoxia mono-culture, hypoxia
co-culture, normoxia mono-culture and normoxia co-culture conditions. Before
hypoxia, the gas-tight chamber (129, 140) as well as the low glucose color free
DMEM medium was flushed with 5% CO2 and 95% N2 for 10 minutes. Then all
plates were washed, and refilled to 1 ml with the pre-treated medium. For coculture, an insert was set in the plate, and freshly thawed HUCB cells were
directly pipetted into the inserts at a concentration of 500,000/well. The 0.4 μm
millipore (Millipore Inc) inserts allow medium to freely circulate through the entire
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culture while not allowing the cells to pass. Hypoxia groups were exposed to
hypoxia (5% CO2 and 95% N2 ) at 37oC for 2 hour, while the normoxia groups had
the same media as the hypoxia group but were maintained under normoxic
conditions for 2 hour. As an additional control, HUCB cells cultured alone were
treated in hypoxia and normoxia conditions as described above. After that, the
media were harvested for future use.

5.3.3 FDA/PI Staining
Cell viability was determined by Fluorescein Diacetate /Propidium Ioidide
(FDA/PI) staining. Briefly, FDA stock solution (5 mg/ml in acetone) and PI stock
solution (1 mg in 50ml PBS) were prepared and stored at 4°C. FDA working
solution (5 μl FDA stock solution in 1 ml PBS) was prepared freshly before use,
and 100 μl working solution was added to the 30 μl PI stock solution as FDA/PI
working solution. Then 30 μl FDA/PI was added into each well containing 600 μl
PBS, and cells were incubated at room temperature for 5 minutes.
Photomicrographs were taken under epifluorescence from five fields for each
sample, which includes the center, left, right, up and down, and the number of
live (FDA labeled) or dead (PI labeled) cells were counted using Image ProPlus
software. The viability of each sample was determined as the percentage of live
cells and was expressed as mean ±sem. These data were then analyzed using
Student’
s t tests.
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5.3.4 Cytokine ELISA
The ELISA was performed according to the manufacturer’
s protocol
(Amersham Bioscience). Briefly, the standard dilution buffer was added to the
“zero”well, and the wells reserved for chromogen blank were left empty. The
standard solution was added to the wells with 100 μl volume, and 50 μl samples
from medium and 50 μl standard dilution buffer were added into the plates to
make all the wells have the same volume. Then, 50 μl of biotinyltated anti- IFN γ
(or any other cytokine to be tested, see Table 5.1) solution were added into each
well except the chromogen blanks. The plates was covered and incubated for 30
minutes at room temperature. The plates were washed 4 times, and100 μl
streptavidin-HRP working solution was added to each well except the chromogen
blank well. After 45 minutes of incubation, the plates were washed 4 times, and
100 μl stabilized chromogen from the kit was added in each well. The plate then
turned blue and it was further incubated for 30 minutes. The reaction was
stopped with the 100μl stop solution. Then the concentration of cytokines was
determined on a plate reader with light absorbance at 450nm. For each condition,
there were 6 samples, and each sample was examined in triplicate. The data are
expressed as mean + sem concentration in pg/ml and were analyzed using
Student’
s t tests.
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Table 5.3. Parameters of ELISA assay
Cytokines

Standard Curve

Sensitivity

IL-1 β

0- 2000 pg/ml

> 3 pg/ml

IFN γ

0 - 1400 pg/ml

> 13 pg/ml

IL-6

0 –2000 pg/ml

> 8 pg/ml

IL-10

0- 1000 pg/ml

> 5 pg/ml

5.4 Results:
5.4.1 Neuron Cell Viability
Hypoxia decreased neuronal viability in hypoxic neuron mono-culture, while
HUCB cells significantly protected neurons from the hypoxia- induced cell death
(Fig 5.1 * p<0.05).
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Fig. 5.1 Neuron viability. A. FDA/PI staining of neuron (x20). Live (FDA labeled)
cells were observed in green, while PI labeled dead cells were red. B. Neuron
viability.

5.4.2 Neuronal IFNγExpression
IFN γ concentration was detected in the medium from normoxic neuronHUCB cell co-culture but was undetectable or below the sensitivity of the ELISA
in the other conditions (Fig 5.2). However, there was a tendency for IFN γ
concentration to be higher in hypoxic co-culture than in hypoxic mono-culture.
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Fig 5.2. IFN γ expression in neuronal cultures. IFN γwas detected in
medium from neuron- HUCB co-culture under normoxic conditions, whereas it
was below the level of sensitivity in the other conditions.

5.4.3 Neuron IL-1β beta and IL-6 expression
IL-1 βand IL-6 were undetectable in the neuronal cultures.

5.4.4 Neuron IL-10 expression
IL-10 was observed in hypoxic co-culture medium, while it was undetectable
in other groups.
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Fig 5.4. IL-10 expression in neuronal cultures. IL-10 was detected in the
hypoxic co-culture group, but it was below the sensitivity level in the other
conditions.

5.4.5 Astrocyte cell viability
Viability of astrocytes was greater in the HUCB co-culture under hypoxic
conditions compared to hypoxic monocultures (Fig 5.5 B *, p<0.05). While there
were no significant differences between other groups. This is clearly visible in the
photomicrographs of FDA/PI labeling of the cells in Fig 5.5 A.
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Fig.5.5. Astrocyte Viability. A. FDA/PI labeling of astrocytes (x20). Live (FDA
labeled) cells were observed in green, while PI labeled dead cells were red. B.
Astrocyte viability

5.4.6 Astrocyte IFN γ expression
IFN γconcentration was below the sensitivity limits of the assay in hypoxic
co-cultures of HUCB cells and astrocyte, and normoxic mono-culture. It was only
detected in hypoxic mono-cultures and normoxic co-cultures (Fig. 5.6).

102

Concentration(pg/mL)

Astrocytes IFN-gamma expression
18
16
14
12
10
8
6
4
2
0
Hypoxia+HUCB

Hypoxia-HUCB

Normoxia+HUCB Normoxia-HUCB

Fig 5.6. Astrocyte IFNγ expression. IFN γ was detected in the medium
from hypoxic mono-culture and normoxic co-culture, while the concentrations
in the other groups were below the detection level of the assay.

5.4.7 Astrocyte IL-1βbeta expression
No IL-1 β level was observed in the astrocyte culture.

5.4.8 IL-6 expression
In astrocytes, IL-6 was observed in the normoxia astrocyte co-culture
condition. After hypoxia, there was a significant decrease in IL-6 concentration in
the co-culture (Fig 5.4*, p<0.05). IL-6 was not expressed in the other conditions.
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Fig 5.8 IL-6 expression in astrocytes. No IL-6 was detected in hypoxic and
normoxic mono-culture medium, and there was a significant difference
between hypoxic co-culture and normoxic co-culture (*, p <0.05).

5.4.9 Astrocyte IL-10 Expression
HUCB significantly elevated IL-10 concentration in hypoxia cultured
astrocytes compared to hypoxic monoculture (* p <0.05, Fig 5.9). In addition, IL10 from hypoxic co-culture was significantly higher than it was in normoxic coculture (#, p<0.05) and normoxic mono-culture (##, p<0.05).
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IL-10 Expression in Astrocytes

Concentration (pg/ml)

120
100

##
#
*

80
60
40
20
0
Hypoxia+HUCB

Hypoxia-HUCB

Normoxia+HUCB Normoxia-HUCB

Fig 5.9 Astrocyte IL-10 expression. IL-10 was significantly higher in hypoxic
co-culture medium compared to the medium in hypoxic mono-culture (*,
p<0.05). It was also significantly higher than normoxic co-culture (#, p<0.05)
and mono-culture (##, p<0.05). No other differences were found among other
groups.

5.4.10 IFN γ, IL-1β, IL-6 and IL-10 in cord blood media
IFNγ, IL-1β, IL-6 and IL-10 were undetectable in all HUCB alone media,
including normoxic cultured HUCB media and hypoxic cultured HUCB media.
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5.5 Discussion:
In this study, the FDA/PI assay was used to examine the cell viability of
neurons and astrocytes. It was found that HUCB cells could significantly improve
neuron and astrocyte survival during hypoxia. Since there was a Millipore
membrane at the bottom of the inserts, which separated the HUCB cells from the
cultured neural cells, and only allowed media across the membrane, it is unlikely
that increased survival was a function of direct interaction between HUCB with
the neurons or astrocytes. Therefore, soluble molecules may play a critical role in
this process.

The expression of pro-/anti-inflammatory cytokines was also examined in
this study. For neurons, IFN γwas only found in the normoxic co-culture
conditions, and the level of IFN γin hypoxic groups was below the detection level
of the assay. The results were consistent with previous literature. Since IFN γis
mostly produced by T cells (209), and neurons are not the major cellular source
of IFN γ, we did not expect to see IFN γexpression in the neuron mono-cultures
under hypoxic or normoxic conditions. When HUCB cells were added, there was
a significant increase of IFN γin the normoxic condition compared with the
monoculture group, suggesting the major source was from HUCB cells. However,
no IFNγwas detected in all HUCB mono-cultured conditions, therefore it is most
likely IFN γ was the product of the interaction between neurons and HUCB cells.
But the mechanism is not clear. In this experiment, even though IFN γwas below
the detectible level under hypoxic conditions, there was a tendency for IFN γ
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from the co-culture medium to be higher than it was from mono-culture. However,
this low level of IFN γmay not be enough to lead to neuronal injury.

As for astrocytes, IFN γ production was observed in hypoxic mono-culture
and normoxic co-culture, while IFN γin the other two groups was under the
detectable level. IFN γis a neurotrophic factor for astrocytes, promoting
astrocyte proliferation and even astrogliosis (210,211). However, extensive
astrocyte activation has serous side effects. Reactive astrogliosis after CNS
injury has been considered a major impediment to axonal regeneration. IFN γ
also modulates MHC class I and class II antigen expression on astrocytes. MHC
class I can elevate astrocyte susceptibility to lysis by class I restricted T
lymphocytes, and MHC class II makes astrocytes function as antigen presenting
cells, which enhance the inflammatory response after injury. In addition, IFN γ
can induce cytotoxins including nitric oxide (212), free radicals, TNFα, IL-1β
production, and all of them may exacerbate the brain damage. Our results
suggested that HUCB cells could suppress astrocyte activity under hypoxic
conditions, which in turn may inhibit the inflammatory response.

IL-1β is a pro-inflammatory cytokine and plays a key role in modulation of
the inflammatory response in the CNS. The cellular source of IL-1βin the CNS
includes all cell types of the brain, although it is undetectable in normal healthy
brain. The IL-1βproduction probably is the result of cell interactions in the CNS,
especially with astrocytes. For example, the production of IL-1βin astrocytes
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was demonstrated in vivo with various animal models (213). In contrast,
astrocyte enriched cultures failed to produce any IL-1βunder exposure to a wide
range of stimuli including LPS, IL-1, TNFα(214), suggesting some molecules
secreted by other cells are important for IL-1βproduction in astrocytes. The
secreted IL-1βcan bind the IL-1β receptor on the surface of astrocytes, and
regulate the function of the astrocyte. Astrocytes are rich in IL-1β receptors (215).
When these receptors are bound with IL-1β, it could greatly decrease IL-1β
concentration in medium. This may be the reason IL-1βwas undetectable in our
study. As for IL-1β in neuronal culture, evidence suggested that while neurons
may produce IL-1β, it is not normally detected (216). Our data were consistent
with this, since no IL-1 βwas observed in the normoxic neuronal monoculture.

In the CNS, the neurons, astrocytes and microglia are the cellular source
of IL-6 (217). IL-6 functions as a neurotrophin in response to neural injury. It can
increase the survival rate of primary neurons in culture (218), and protect primary
neurons against glutamate toxicity, and rat cholinergic neurons against the
neurotoxic effect of N-methyl-D-aspartate (219). In glial cells, IL-6 promotes
astrocyte proliferation, and is believed to be involved in astrogliosis (220).
However, over-expression of IL-6 is deleterious to the CNS. The high level of IL-6
is associated with neurodegeneration, break down of the BBB, angiogenesis,
increased expression of complement proteins, and impaired learning (221, 222).
Chronic IL-6 expression may cause profound cerebellar pathology, and
significantly change the electrical and synaptic activity of Purkinje neurons in
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mice (223). In contrast, IL-6 knock out mice had a correlative decrease in brain
damage compared to control animals following a focal cryo injury to the frontoparietal cortex (194). However, where the dosage of IL-6 turns from beneficial to
deleterious is not clear, and it greatly depends on different animal species,
animal models and microenvironment. Definitely, low concentrations of IL-6 are
not harmful for neural cells. In this study, IL-6 was not detected in any of the
neuronal groups, suggesting IL-6 was not involved in the HUCB neuroprotection.
As for astrocytes, IL-6 was only observed in the co-culture condition, and IL-6
level was significantly higher in normoxic compared to hypoxic condition. At this
high level, the potential harm of IL-6 may be lessened since no stressful stimuli
existed. Under hypoxic conditions, IL-6 level was significantly higher in the coculture medium than in monoculture, which may have decreased astrocytes
death in HUCB co-cultured group.

Unlike the pro-inflammatory cytokines, IL-10 is an anti-inflammatory
cytokine, which functions as a neurotrophic factor and inflammatory inhibitor. The
major cellular source is macrophage. IL-10 has the capacity to inhibit the
production of soluble inflammatory mediators, including oxygen or nitrogen
derived free radicals, and a variety of cytokines. Treatment with IL-10 could
significantly attenuate the brain damage in stroke (224), and has been show to
improve the neurological recovery in traumatic brain injury (206). The functional
recovery observed with HUCB delivery after stroke may be attributed to the antiinflammatory effects of IL-10, as well as to the neurotrophic effect of this cytokine.
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In our study, there was more IL-10 in hypoxia exposed co-cultured groups
compared to the monoculture groups for both neurons and astrocytes.

Our results suggested that HUCB could selectively decrease the
production of pro-inflammatory IFN gamma, and increase the level of antiinflammatory cytokine IL-10 in hypoxic media. This inhibited inflammatory
response could protect neurons and astrocytes from hypoxia induced cell death.

110

CHAPTER SIX
THE INTERACTION OF NEURONS, ASTROCYTES, AND MICROGLIA WITH
CD8, CD11B, CD19 POSITIVE CELLS DERIVED FROM HUMAN UMBILICAL
CORD BLOOD

6.1 Abstract:
BACKGROUND AND PURPOSE: When intravenously administered into rats that
have undergone middle cerebral artery occlusion (MCAO), HUCB cells
decreased leukocyte infiltration into the stroked brain, which was accompanied by
a decrease in pro-inflammatory cytokine production in the central nervous system
(CNS). However, the mechanism of action underlying this response is not clear.
METHODS: In this study, three main subpopulations of HUCB cells (CD8+ T cells,
CD11b+ monocytes and macrophage, and CD19+ B cells) were isolated from
HUCB, and cultured with or without neurons, astrocytes and microglia individually
in hypoxia for 2 hours. The medium was collected and the cytokines, including IL1β, IL-6, IL-10, and IFNγwere examined by ELISA.
RESULTS: It was found that CD11b+ and CD19+ cells significantly decreased
microglia viability in CD11b+ (or CD19+) HUCB and microglia co-cultures in
comparison to microglial monoculture under hypoxic and normoxic conditions,
while CD8+ cells significantly decreased astrocyte viability but not microglial
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viability. No significant changes in cytokine expression were observed in this
study.
CONCLUSIONS: The data were partly consistent with the previous study that
HUCB cells promoted microglial cell death. The neuroprotective effect of HUCB
may be attributed to the effect caused by interactions between the
subpopulations of HUCB, which can not be achieved in CD8+, CD11b+ or CD19+
alone.

Key word: human umbilical cord blood, CD8, CD11b, CD19, inflammatory
cytokines
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6.2 Introduction
The HUCB cells have been applied in the clinic as a transplantation
treatment for severe hematopoietic diseases for many years. HUCB contains
similar numbers of stem cells as bone marrow, and it is used in transplantation
therapy for reconstitution of the blood lineages after severe myeloid depletion
(225). Compared to bone marrow, HUCB has a lower incidence of morbidity and
mortality, and graft -versus-host diseases (226). When HUCB was intravenously
administered into stroked animals, there was a decreased CD45/CD11b positive
(+) and CD45/B220+ cellular infiltration observed in the stroked brain of recipients.
This decrease was accompanied by a decrease in mRNA and protein expression
of pro-inflammatory cytokines and a decrease in nuclear factor κappa B (NF-κB)
DNA binding activity in the brain of stroked animals treated with HUCB (171). In
addition, we observed microglial cell death when these cells were cultured with
HUCB under hypoxic conditions, while HUCB prevented hypoxia- induced cell
death of neurons and astrocytes. These changes in cell viability may be coupled
with pro-/anti- inflammatory cytokine imbalances, and may account for the
decreased inflammatory response after HUCB transplantation. However, which
subpopulation of HUCB has this function is not clear.

HUCB is a very heterogeneous cell population. Among the cells in the
preparation are three main subpopulations, including T cells, B cells and
monocytes. These cells have specific linage markers, CD8 (or CD4), CD19 and
CD11b respectively. CD8+ cells are cytotoxic T cells activated by Class Іantigen
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presenting cells with pathogen attacking effects (227). In contrast, CD4+ cells are
activated by class II MHC antigen presenting cells, and do not attack pathogens
directly. Instead, they can modulate cytokine expression, and regulate the
immune response as helper cells (228). CD8+ cells can also produce cytokines
(229, 230) similar to CD4+ cells. In addition, CD8+ cells produce chemokines
(231,232), which may work with cytokines and indirectly promote target
destruction and/or recruit additional effector populations to the site of injury.
Therefore, CD8+ cells were studied in this experiment. CD11b+ cells are
monocytes. Under healthy physiological conditions, CD11b+ exists in intracellular
granules. CD11b is a marker on the surface of monocytes, and increases
following stimulation. Increased CD11b promotes firm attachment of the
monocytes to the endothelium, which then allows transendothelial migration into
the inflamed tissue (233). The translocated monocytes have endocytotic function,
and become microglia or macrophage depending on their different locations.
CD11b+ cells produce free radicals and cytokines including TNF-α, IL-1β, and IL6 in response to antigen stimulation (234). CD19 is a B-lineage-specific antigen, a
molecule expressed on normal and neoplastic B cells (235). B cells not only
produce antibody in response to antigen invasion, but also play a variety of
immunoregulatory roles through their antigen presenting ability and through
cytokine and chemokine production (236, 237).

In this study, CD8+, CD11b+, or CD19+ cells were isolated from HUCB
through magnetic cell sorting, and cultured with neurons, astrocytes and
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microglia respectively. The pro-/anti-inflammatory cytokine expression was
investigated and discussed.

6.3 Material and Methods

6.3.1 Neuron and Astrocyte Preparation
Rat embryonic cerebrocortical neuronal cells were purchased from
Celprogen Inc (Cat# 12030-01), and cultured in the medium provided by the
company. Astrocytes were isolated from fetal rat brain at E 17 (238).The brain
was minced in Earle's Balanced Salt Solution (EBSS) containing 20 μg/ml DNase
and 0.3% Bovine Serum Albumin (solution A) on ice. Following this, the
homogenate was centrifuged at 500 g for 2 min, and the pellet collected and
incubated in EBSS containing 0.025% trypsin, 60 μg/ml DNase and 0.3% Bovine
Serum Albumin (solution B) at 37°C for 15 min to dissolve the connective tissue
between cells. Trypsinization was stopped with 10% fetal calf serum (FCS), and
the solution was centrifuged again at 500g for 2 min. The pellet was resuspended
in solution A and triturated through a fire-polished Pasteur pipette. The solution
was allowed to settle for 4 minutes and the supernatant was collected. Then
more solution A was added to the pellet and the process repeated twice. The
collected supernatant was combined and centrifuged at 500 g for 5 min. The
pellet with cells was resuspended in culture medium (DMEM supplemented with
10% (v/v) FCS) and plated at a density of 2.5×105 cells/cm 2 in a flask coated with
poly-L-lysine. Isolated cells were cultured at 37°C with 5% CO 2 and media were
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changed on day 2 and day 4 after culture, and cells were subcultured on day 7
and grown to confluency. Since neurons and microglia cannot proliferate and die
in long term culture, the majority of cells leftover are astrocytes.
6.3.2 Isolation of Microglia

Microglia were isolated from fetal rat brain at E 17 (239).The brain was
minced in Earle's Balanced Salt Solution (EBSS) containing 20 μg/ml DNase and
0.3% Bovine Serum Albumin (solution A) on ice. Following this, the homogenate
was centrifuged at 500 g for 2 min, and the pellet collected and incubated in
EBSS containing 0.025% trypsin, 60 μg/ml DNase and 0.3% Bovine Serum
Albumin (solution B) at 37°C for 15 min to dissolve the connective tissue between
cells. Trypsinization was stopped with 10% fetal calf serum (FCS), and the
solution was centrifuged again at 500 g for 2 min. The pellet was resuspended in
solution A and triturated through a fire-polished Pasteur pipette. The solution was
allowed to settle for 4 minutes and the supernatant was collected. Then more
solution A was added to the pellet and the process repeated twice. The collected
supernatant was combined together and centrifuged at 500 g for 5 min. The pellet
with cells was resuspended in culture medium (DMEM supplemented with 10%
(v/v) FCS) and plated at a density of 2.5×105 cells/cm2 in a flask coated with polyL-lysine. Isolated cells were cultured at 37°C with 5% CO2 without medium
change for 5 days. The cells were cultured until confluency, and the confluent
culture was placed on a rotary shaker and agitated for 1 hour at 37°C. The media
was collected and spun down. The cells were resuspended in serum free DMEM
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and plated at 100,000 cells/ml into culture flasks and maintained at 37°C with 5%
CO2 for 1 hour. Loosely adherent oligodendrocytes were floated from the wall of
culture dishes by gently shaking with the hand. The medium was removed gently
and more serum free DMEM was added to the dishes. This procedure was
repeated twice. The remaining adherent cells were purified microglia. The
resulting cells were cultured with medium (DMEM with 10% FBS and 0.1%
gentamicin) until use.

6.3.3 HUCB subpopulation isolation

CD8+ T cells, CD11b+ monocytes and CD19+ B cells were isolated from
HUCB with magnetic cell sorting methods. Briefly, cryopreserved HUCB
(Saneron CCEL Therapeutics, Inc, Tampa FL) was freshly thawed into 1 X BD
Image buffer (BD bioscience, cat. No. 552362), and the cell concentration was
adjusted to 107 cells per 90 µl. The HUCB cells were incubated with 10 µl antiCD8 linked microbeads (BD Bioscience, cat. No. 557765), anti-CD11b linked
microbeads (MACS, No. 130049601), or anti-CD19 microbeads (BD Bioscience,
cat. No. 551521) at room temperature for 15 minutes. The solution was
centrifuged at 1000g for 10 minutes, and washed with 1 X BD Image buffer 20
times, and supernatant was removed completely. The pellet was resuspended,
and the cell concentration was adjusted to 2 X 107cells/ml in cold 1 X BD Image
buffer. The labeled cell suspension was transferred to the positive-fraction
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collection tubes (12 X 75mm tubes), and placed into the magnetic holder for 6
minutes. The positively labeled cells were attached to the wall of the tube, and
negative cells sank to the bottom of the tube or remained suspended in the
medium. The supernatant was removed, and the cells on the wall were collected.
The collected cells were resuspended and the cell sorting procedure was
repeated twice with 2 minute incubations.

6.3.4 Cell Culture and Hypoxia Treatment
Neurons (astrocytes, or microglia) were grouped into hypoxia monoculture, hypoxia co-culture, normoxia mono-culture and normoxia co-culture.
Before hypoxia, the gas-tight chamber (129, 140) as well as low glucose color
free DMEM medium was flushed with 5% CO2 and 95% N 2 for 10 minutes. Then
all plates were washed, and refilled to 1 ml with the pre-treated medium. For coculture, an insert was set in plate, and CD8+, CD11b+ or CD19+ HUCB cells
were directly pipetted into the inserts at the concentration of 100,000/well. The
0.4 μm millipore (Millipore Inc) inserts allow medium to flow freely in and out of
the inserts while keeping the HUCB subpopulation cells and neural cells
separated. Hypoxia groups were exposed to hypoxia (5% CO2 and 95%N2) at
37oC for 2 hour, while the normoxia groups were cultured in low glucose media,
but under normoxic conditions for 2 hour. After that, the media were harvested
and stored at -80o C for future analysis.
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6.3.5 FDA/PI Staining
Cell viability was determined by Fluorescein Diacetate /Propidium Iodide
(FDA/PI) staining. Briefly, FDA stock solution (5mg/ml in acetone) and PI stock
solution (1 mg in 50ml PBS) were prepared and stored at 4°C. FDA working
solution (5μl FDA stock solution in 1 ml PBS) was freshly prepared before use,
and 100μl FDA working solution was added to 30μl PI stock solution to form the
working solution. Then 30μl FDA/PI was added into each well containing 600 μl
PBS, and the cells were incubated at room temperature for 5 minutes.
Photomicrographs were taken under epifluorescence, and the number of live
(FDA labeled) or dead (PI labeled) cells were counted using Image ProPlus
software. The number of surviving cells is expressed as a percentage of the total
population/field of view. These data are averaged and expressed as mean + sem
and then analyzed using Student’
s t tests.

6.3.6 Cytokine ELISA Assay
The ELISA for IFNγ, IL-1β, IL-10 and IL-6 were performed by Pierce
Endogen Biotechnology using the Searchlight technology (Pierce Biotechnology).
The commercial Searchlight plates were pre-coated with specific antibodies with
a 2X2 pattern in each well. The standard and samples were added into the plate
according to the instructions, and the plates were incubated at room temperature
one hour or long enough for the protein present in sample and standard to
capture the antibody. The plates were then incubated with streptavidinhorseradish peroxidase (HRP), and the luminescent signal was measured in a
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plate reader and the expression of IFNγ, IL-1, IL-6 and IL-10 analyzed using
ArrayVision customized software. The data are expressed as mean + sem
concentration in pg/ml and were analyzed using Student’
s t tests.

6.4 Results
6.4.1 IFNγ and IL-10 expression.
IFNγand IL-10 were undetectable under all the conditions.

6.4.2. The interaction of CD11b+ HUCB cells with neurons, astrocytes and
microglia
6.4.2.1 Effect of CD11b+ HUCB cells on neural cell viability
The cell viability was assayed with FDA/PI staining, photographed and
quantified using Image ProPlus software. CD11b+ cells significantly decreased
microglial viability compared to the mono-cultured microglia under hypoxia (*,
p<0.05) and normoxia (#, p<0.0), while it had no effect on astrocytic and neuronal
viability (Fig 6.1).

6.4.2.2 IL-1β and IL-6 expression in CD11b+ HUCB culture of neural cells.
No significant differences were observed between groups, but there was a
tendency for IL-1 βconcentration to be higher in the CD11b+/ co-cultured
microglia than the mono-cultured microglia under hypoxic as well as normoxic
conditions (Fig 6.2). In contrast, neurons and astrocytes had a tendency to have
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a lower IL-1β concentration in medium from the co-cultures compared to monoculture medium in normoxic conditions. The similar trend was observed in the
hypoxia culture (Fig 6.2).

Interestingly, IL-6 concentration followed a similar pattern as IL-1 β. IL-6
tended to be higher in co-culture medium than mono-culture medium under
hypoxic as well as normoxic conditions, while it was opposite in neurons and
astrocytes (Fig 6.3). No significant differences were observed in any groups.
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Fig 6.1 Neural cell viability with/without CD11b. CD11b+ HUCB cells
significantly decreased microglial viability in co-culture compared to microglia
monoculture under hypoxia exposure (* p<0.05). Similar phenomenon were
observed in the normoxic condition with co-cultured microglia having lower
viability than microglia in monoculture (#, p<0.05). There were no significant
differences among neuronal groups and astrocytic groups.
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Fig 6.2. IL-1 beta expression with/without CD11b. CD11b+ HUCB cells had a
tendency to have decreased IL-1β concentration in hypoxia exposed neuron and
astrocytes, while IL-1β concentration tended to be higher in co-cultured microglia
than in mono-culture under hypoxic as well as normoxic conditions. No significant
differences were observed between groups.
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Fig 6.3. IL-6 expression with/without CD11b. No significant differences were
observed between all groups. However, in the hypoxic or normoxic conditions, IL6 tended to have a lower concentration in CD11b+ HUCB co-cultured astrocytes
and CD11b+ co-cultured neurons compared to astrocyte mono-culture and
neuron mono-culture respectively, while in microglial cultures, the opposite was
true.

6.4.3. The interaction of CD8+ HUCB cells with neurons, astrocytes and
microglia
6.4.3.1 Effect of CD8+ HUCB cells on neural cell viability
Unlike CD11b+ cells, CD8+ cells had no effects on microglial and neuronal
viability. Instead CD8+ cells significantly decreased the astrocyte viability
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compared to mono-cultured astrocytes under hypoxic (*, p<0.05) or normoxic (#,
p<0.05) conditions (Fig 6.4)
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Fig 6.4 Neural cell viability with/without CD8. CD8+ cells significantly
decreased co-cultured astrocyte viability compared to mono-cultured astrocytes
under hypoxic conditions (* p<0.05). This was true in normoxic conditions as well
(# p<0.05). CD8 did not significantly affect the viability of neuron and microglia in
culture.

6.4.3.2 IL-1β and IL-6 expression in CD8+ HUCB culture of neural cells.
CD8+ HUCB cells incubating with astrocytes had a tendency to increase
IL-1 βconcentration compared to mono-cultures of astrocytes under hypoxic or
normoxic conditions; the greatest effect was observed in the normoxic condition.
IL-1β in neuron and microglial cultures was undetectable (Fig6.5).
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Hypoxia tended to increase IL-6 production in the medium collected from
neuronal and microglial cultures, but there were no significant differences
between the co-culture and mono-culture groups (Fig 6.6).For the astrocyte
cultures, CD8+ HUCB cell tended to increase IL-6 concentration in the media in
comparison of the mono-cultures under hypoxic and normoxic condition (Fig 6.6).
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Fig 6.5 IL-1 beta expression with/without CD8. IL-1βwas negligible in the
media from neuronal and microglial cultures, and no significant differences were
observed between all groups. However, in the astrocyte culture there was a
tendency for increased IL-1βpresence in media from CD8+ HUCB / astrocyte coculture in both normoxia and hypoxia conditions.
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Fig 6.6 IL-6 expression with/without CD8. No significant differences were
observed between all groups. But CD8+ HUCB cells tended to elevate IL-6
concentration when co-cultured with astrocytes in hypoxic or normoxic conditions
compared with mono-cultured astrocytes. For all conditions, there was a
tendency for hypoxia exposed cultures to have a higher IL-6 concentration in
media compared to the corresponding normoxia groups.
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6.4.4. The interaction of CD19+ HUCB cells with neurons, astrocytes and
microglia
6.4.4.1. Effect of CD19+ HUCB cells on neural cell viability
CD19+ HUCB cells significantly decreased microglial viability compared to
mono-cultured microglia exposed to hypoxia (*, p<0.05). Similar results were
observed in normoxia cultures (#, p<0.05). Interestingly, lower astrocyte viability
was observed in normoxic CD19 astrocyte co-culture in comparison to hypoxic
astrocyte monoculture (##, p<0.05) (Fig 6.7).
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Fig 6.7 Neural cell viability with/without CD19. It shows microglia in co-culture
with CD19+ HUCB cells had a lower viability than those monoculture under both
hypoxic (*, p<0.05), and normoxic condition (#, p<0.05).
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6.4.4.2 IL-1β and IL-6 expression in CD19+ cells HUCB cells co-culture with
neural cells.
No significant differences of IL-1βconcentration were observed in the
media between groups (Fig 6.8), but medium from CD19+ HUCB microglia or
astrocytes co-cultures tended to have an increase IL-1β concentration in
comparison to the respective mono-cultures in hypoxic or normoxic conditions.
This tendency was most pronounced in the astrocyte co-culture in normoxia (Fig
6.8).

Hypoxia tended to decrease IL-6 concentration in neuronal culture
compared to the normoxic cultures, and the media from neuronal co-culture
tended to have a higher IL-1βconcentration than the media collected from monocultured neurons under hypoxic conditions. The same was true in normoxia,
although no significant differences in IL-6 were observed (Fig 6.9).
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Fig 6.8. IL-1 beta expression with/without CD19. In both hypoxic and
normoxic conditions, IL-1βconcentration tended to increase in CD19+ co-culture.
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Fig6.9. IL-6 expression with/without CD19. Co-culturing neurons, astrocytes,
microglia with CD19+ HUCB cells had no significant effect on IL-6 secretion into
the culture medium.
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6.5 Discussion
Previous studies found that human umbilical cord blood (HUCB) cells can
promote microglial death, and simultaneously prevent astrocytic and neuronal cell
death from hypoxia. However, the mechanisms that underlie these effects were
unknown. In this study, CD8+, CD11b+ and CD19+ cells were isolated from
HUCB, and incubated with microglia, neurons, and astrocytes individually. It was
found that CD11b+ and CD19+ HUCB cells significantly decreased microglial
viability compared to microglia monocultures under hypoxic and normoxic
conditions. Interestingly, CD8+ HUCB cells decreased astrocyte viability under
hypoxic and normoxic conditions. No other significant differences in cell viability
were found.

These changes in cell viability were not accompanied by significant
changes in IL-1βor IL-6 concentration. IFNγ and IL-10 were not detected in any
of the cultures, which suggest that these cytokines at least were not involved in
neural cell death when the neural cells were co-cultured with subpopulations of
HUCB. This was not true when HUCB cells interacted with microglia, astrocyte
and neurons individually as a whole. The increased IFNγin the co-culture
promoted microglial death, while IL-10 benefited astrocyte and neuron survival
under hypoxic conditions as we discussed in the previous two chapters. This
suggests that the interaction between each subpopulation of HUCB is what
modulates IFNγand IL-10 expression.
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6.5.1 The effect of IL-1βand IL-6 on neurons
As an inflammatory cytokine, IL-1βis excitotoxic to neurons. Clinic cases
demonstrate that IL-1βlevel significantly increases in cerebrospinal fluid shortly
after severe traumatic injury in human, and this increase is associated with
neuronal damage in the ipsilateral hemisphere (240). Patients with high IL-1βin
CNS have issues with metabolic regulation, temperature regulation, sleep, food
and water intake, and memory functions. These deleterious effects have been
found in a number of animal models of neurodegenerative diseases, including
hypoxic-ischemic (H/I) insult, brain trauma, multiple sclerosis, and Alzheimer’
s
disease. In a brain injury animal model induced by metabotropic glutamate (MGlu)
injection, a progressive neuronal loss existed in cortex and striatum; at least in
striatum this neuronal injury occurred within a similar time frame and region as IL1β expression (241). In addition, an exacerbated neuronal cell loss was observed
in IL-1βreceptor antagonist knock out animals after injection of beta-amyloid (Aβ),
where IL-1β signal is enhanced since there is a loss of the IL-1 receptors’
physiological antagonist (242). In contrast, inhibition of IL-1 activity, either
through neutralizing antibodies, or through blockade of the receptor, ameliorated
functional outcome (243). However, IL-1βalone does not induce death in
otherwise healthy neurons. Therefore, it is hard to evaluate the role of IL-1βin
neuronal culture. Recently, Viviani et al (2003) determined that IL-1βhad no
effect on cell viability of primary hippocampal neurons in culture, but it
significantly increased N-methyl-D-aspartic acid (NMDA)- induced cell death. IL1β caused 30% more neuronal death than NMDA treatment only. This cell death
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could be blocked by both lavendustin A and PP2 (4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-d]pyrimidine), the tyrosine kinase inhibitors, suggesting this
cell death was mediated through the tyrosine kinase pathway (238).

Unlike IL-1β, the literature strongly suggests that IL-6 is a neurotrophic
factor in vitro rather than an inflammatory cytokine. For example, IL-6 stimulated
PC12 cells to sprout neural processes, and express a number of neuronal
markers after stimulation. Further, IL-6 was shown to protect dopaminergic
neurons from the injury caused by 1-methyl-4-phenylpyridinium (MPP +) in vitro
(244). In addition, IL-6 not only supports the survival of catecholaminergic cells
but also cholinergic neurons (245, 246).

6.5.2 The effect of IL-1βand IL-6 on microglia and astrocytes
As for astrocytes and microglia, IL-1βserves as a mediator of cell
activation, and promotes glial cell proliferation. When infused into rat brain, IL-1β
induces astrocyte gliosis, and enhances immunoreactivity of Glial Fibrillary Acidic
Protein (GFAP) (247). In a corticectomy injury model, astrocytes failed to upregulate expression of the neurotrophic factor Ciliary neurotrophic factor (CNTF)
following CNS injury in mice deficient in IL-1β, and this abnormal lack of CNTF
elevation could be rescued by the application of exogenous IL-1β(239). In a
cuprizone model of demyelination and remyelination, the authors showed IL-1β
deficient mice failed to remyelinate properly, and this failure correlated with
delayed differentiation of oligodendrocyte precursors and with a lack of astrocytic
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and microglial production of Insulin-like growth factor 1 (IGF-1) (184). In addition,
IL-1βhas an indirect trophic effect on glial cells. In a traumatic brain injury (TBI)
model, IL-1βantagonist diminishes the inflammatory response caused by injury,
and at the same time, antagonist also inhibits Nerve growth factor (NGF)
production in astrocytes, which in turn hampered glial and other neural cells
recovery (214). The gliosis effect of IL-1βis also supported by results obtained in
vitro using primary astrocyte and microglia cultures. Application of exogenous IL1β to such cultures induces IL-6, CNTF, and NGF expression (248). Most of
these cytokines and growth factors are known to induce neuronal and glial growth
and survival. For example, in primary astrocyte cultures from neonatal rats, IL-1β
was shown to induce proliferation of astrocytes (249), as well as increasing
GFAP immunostaining. In another study, IL-1βwas shown to promote microglial
proliferation after NMDA injury, while IL-1β supplement was not in use, microglial
recovery was slowed down with a blockage of cell proliferation(167). In enriched
brain cell culture, the author even argued that IL-1βwas pivotal for the activation
of microglia and gliosis (247).
IL-6 has a similar effect on astrocytes and microglia. Further it is believed
that the gliosis induced by IL-1βis mediated through the IL-6 pathway. In one
experiment, cytokines IL-6, IL-1βand TNFγwere delivered into the left cerebroventricular system of a healthy rat through convection enhanced delivery (CED)
methods. Gliosis occurred in the left cerebral cortex in IL-6 and IL-1βtreated
groups, while gliosis was not seen in the TNFγtreated groups. When the animals
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were co-treated with propranolol or IL-10, a reagent attenuating the level of IL-6,
the gliosis decreased dramatically to normal levels (250). In a Parkinson mouse
model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
microgliosis was observed in the substantia nigra pars compacta, where
microgliosis started from day 1, and peaked at day 7. When IL-6 mutant animals
were used, there was no microgliosis, suggesting IL-6 is crucial for microgliosis
(251). In vitro, astrocytes cultured from mature bovine brain were shown to
proliferate more rapidly after IL-6 treatment (252). In astrogliomas, IL-6 appears
to promote growth in an autocrine manner (220), and this constitutively
expressed IL-6 sustains astroglioma growth. Neutralizing IL-6 with an antibody or
blocking IL-6 receptor inhibits astroglioma cell proliferation (220). In contrast, over
production of IL-6 in a transgenic mouse was associated with astrogliosis and
increased microglial ramification (253).
Taken together, these data strongly suggested that the function of IL-1β
and IL-6 is to promote gliosis. The activated microglia and astrocytes produce
chemokines (MCP-1, IL-8, IP-10) (255), cytokines (IFNγ, IL-1β, TNFα) (256, 257),
and adhesion molecules (ICAM-1, VCAM-1, E-selectin) (258, 259), most of which
are known to be strongly pro-inflammatory. In addition, activated microglia and
astrocytes also produce NO and other free radicals (260). These small molecules
serve to safeguard the brain against pathogen invasion, and clear away damaged
or dying cells; on the other hand, these elevated pro-inflammatory cytokines and
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free radicals could exacerbate the damage caused by injury and cause cell death
(261).

6.5.3 Effect of CD11b+ HUCB cells on neural cells
In co-cultures of microglia and CD11b+ HUCB cells, there was an
apparent tendency for the concentration of IL-1βto be higher than in the
monoculture groups under hypoxic and normoxic conditions. A similar pattern
was observed for IL-6 concentration in microglia culture. Together IL-6 and IL-1β
should promote microgliosis. However, with the limited time in culture (2 hours) in
this study) it is hard to see how microglia could become gliotic, since the DNA
and protein preparation for cell proliferation takes time. In contrast, these
overlapping gliosis effects of IL-1β and IL-6 may turn out to be a function of free
radical release which could cause microglial death as we discussed above.

As for neurons, the level of IL-1β in all groups was very low and therefore
it is unlikely that this cytokine could affect neuronal viability. Since IL-6 works as a
neurotrophic factor, its slight change in concentration in the different groups did
not impair neuronal viability. A similar IL-1βand IL-6 pattern was observed in
astrocyte culture, where both IL-1βand IL-6 worked as astrogliosis effectors. This
may be the reason that no significant differences in cell viability were observed in
CD11b+ treated neurons and astrocytes with hypoxia exposure.
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6.5.4 Effect of CD8+ HUCB cells on neural cells
The pattern of glial cell death and IL-1βand IL-6 cytokine expression
observed in CD8+ treated astrocyte cultures was similar to that of the CD11b+
treated microglial cell cultures. It is possible that the overlapping effects of IL-1β
and IL-6 triggered the potential gliosis and free radical outburst, which may have
induced astrocyte death. In contrast, the changes of IL-1βand IL-6 in microglia
and neuron culture were slight and may explain why there was no significant cell
death in CD8+ treated microglial and neuronal cultures.

6.5.5 Effect of CD19+ HUCB cells on neural cells
In CD19+ cell treated microglia, IL-1β level appeared higher than in the
microglial mono-culture conditions under both hypoxia and normoxia. Unlike
CD11b+ treated cells, the differences in concentration of IL-6 were not significant
in different microglia cultures as shown in Fig 6.9, perhaps because of limited
sample size. We can only hypothesize that the combined release of IL-6 and IL1βmay have resulted in excess free radical production that induced microglial
death. Interestingly, high levels of IL-1βwere observed in the normoxic astrocyte
CD19 co-culture, and the effect of this high IL-1βwas enhanced by high level of
IL-6 in the same culture. This may be the reason that a significant viability
difference was observed between hypoxic astrocyte monoculture and normoxic
astrocyte CD19+ co-culture (Fig 6.7). Since the variances of IL-1β and IL-6 were
slight in neuron groups, there were no significant viability differences among
neuron cultures with/without CD19 treatment.
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Taken together, these results showed that CD11b and CD19 derived
HUCB cells significantly caused microglial death in microglia co-culture compared
to microglia monoculture, while CD8 derived HUCB cells significantly impaired
astrocyte viability compared to its monoculture. The cell viability changes were
associated with increased IL-1βand IL-6, which may have triggered the free
radical cascade, and caused cell death. Interestingly, no obvious neural
protection was observed in any culture with HUCB subpopulations. However,
when HUCB was co-cultured with microglia, astrocyte and neurons individually, it
promoted microglia death, and prevented neuronal and astrocytic death under
hypoxic conditions. This inconsistency may be attributable to the interactions of
the different subpopulation of HUCB when they are mixed together. For example,
the anti-inflammatory cytokine IL-10 was found in the media from HUCB treated
neural cells in Chapter 4 and 5. IL-10 can modulate gliosis by regulation of IL-6
production (250), prevent neuron death (262) and inhibit free radical production in
immune response (263). Therefore, the high astrocyte death rate in co-cultures of
astrocytes and CD8+ HUCB cells is possibly caused by the over production of IL6 and IL-1β, which may not happen in HUCB culture where IL-10 attenuates the
production of IL-6, and indirectly affects IL-1βeffects. But how the subpopulations
of HUCB interact with each other is not clear, and remains for further
investigation.
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CHAPTER SEVEN
CONCLUDING REMARKS

The actual part of the cord blood that has been used for cell
transplantation is the “mononuclear fraction”, which contains 1% or less stem
cells, 41% T cells, 20% B cells, and 38% monocytes (13, 14, 19). HUCB
transplantation can significantly improve the functional recovery in animal models
of Parkinson disease, spinal cord injury, amyotrophic lateral sclerosis (ALS),
Sanfilippo syndrome, and stroke (3). The HUCB has been delivered directly into
the site of injury, or through intravenous administration. When the two delivery
systems were compared in stroked animals, intravenous administration had
similar effects on functional recovery early after stroke as intracranial
administration. However, the functional recovery in intravenously treated animals
was maintained longer than in animals with intracranial administration (25).
Interestingly, this functional recovery was shown to be dose dependent in stroked
animals (27). Animals that received 106 or more cells had much better behavioral
recovery than animals that received fewer cord blood cells, and this functional
recovery was associated with a smaller infarct volume in comparison to control
animals. It was long thought that stem cells from HUCB could proliferate and
differentiate into neural like cells that could replace the cells lost during the stroke.
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This possibility has been confirmed in that infused HUCB cells were found
in the parenchyma of the injured brain, and expressed neuronal and astrocytic
markers (26). And the extent of functional recovery was directly related to the
amount of cells infiltrating into the injured site. However, how HUCB cells could
get to the injury site after intravenous administration was not clear. One
possibility was that the blood brain barrier was disrupted after injury, and the cord
blood cells could passively leaked into the injured brain. Another possibility was
that some chemokines, MCP-1 and MIP-1α, can induce leukocyte migration
along a concentration gradient. It was found that the expression of chemokines
increased instantly after stroke, and the increase was associated with
mononuclear infiltration into the injury site (118). Therefore, HUCB could actively
migrate to the injury site under the influence of chemokines.

Interestingly, some studies indicated that there are few stem cells in
HUCB, and after intravenous administration, only few cells could infiltrate through
the blood brain barrier to the infarct area (47). In addition, among the infiltrated
cells, few of them differentiated into neural like cells as they usually do in vitro,
where their neural properties could be determined with immunostaining for neural
markers including NeuN, TuJ1, GFAP, etc. (37). Therefore, the cell replacement
mechanism is unlikely. Recently, it was found that HUCB reduced the level of
CD45/CD11b+ and CD45/B220+ cells in stroked brain following intravenous
administration (171). The decreased cell infiltration was accompanied by a
decrease in mRNA and protein expression of pro-inflammatory cytokines and a
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decrease in nuclear factor kappaB (NF-kappaB) DNA binding activity in the brain.
This work was consistent with the comparative study of inflammatory phenotypes
between cord blood and adult blood. Cord blood cells have immature phenotypes
of inflammation with compromised expression of pro-inflammatory cytokines and
high production of anti-inflammatory cytokines including IL-10 compared to adult
blood cells. When transplanted in clinic, there is a lower incidence of graft versus
host disease (GVHD) in HUCB recipients. If GVHD does happen, its severity is
less (70).

Therefore, the suppressed inflammatory response could be the major
mechanism contributory to the functional recovery in stroked animals following
HUCB administration. In this study, the subpopulations of neural cells were
isolated from embryonic day 17 rats, and they were co-cultured with HUCB or its
subpopulations. The role of chemokines on HUCB migration was also in the first
aim of this project. Following that, whether it was just cytokines or the cellular
interactions responsible for inflammation was investigated.

7.1 Chemokines, MCP-1 and MIP-1α, attracted HUCB to the injury site
following stroke
The first question of this project is how HUCB cells can get to the site of
injury in the stroked brain after intravenous administration. One possibility is the
blood-brain-barrier was temporarily opened after injury, which allowed HUCB
cells to passively leak into the CNS. Another possibility is that HUCB cells can
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actively migrate into the injury site under the influence of chemokines.
Chemokine MCP-1 and MIP-1αwere of interest since they are among the most
potent chemokines in the CNS, and they increased shortly after injury. For
example, in a model of hippocampal degeneration caused by axonal injury,
CCR2 (MCP-1 receptor) mutation led to the absence of lymphocyte infiltration in
the CNS, which was not reversible by the presence of any other chemokines,
suggesting the critical role of MCP-1 in lymphocyte migration (121).

Our experiments showed that the expression of MCP-1 and MIP-1α
increased after stroke in rodent animals as determined by western blotting and
immunohistochemical staining. The increased MCP-1 and MIP-1αwere located
in the ipsilateral hemisphere of injury side, and was positively co-stained with
astrocyte, neuron, and microglial markers. However, this increased MCP-1 and
MIP-1αwere of rat origin, and may not have induced human cord blood cell
migration. Therefore, their effect on HUCB migration was further examined with
ex vivo migration assays. The results indicated that rat specific MCP-1 or MIP-1α
alone promoted HUCB cell migration. Tissue extracts from stroked brain
significantly promoted HUCB migration compared to tissue extracts from the
contralateral hemisphere, and this migration was neutralized by application of
MCP-1 or MIP-1α antibodies in the medium. These results were further
confirmed by the constitutive expression of the MCP-1 receptor, CCR2 and MIP1α receptors, CCR1 and CCR5 on the surface of the HUCB cells. Therefore,
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chemokines, MCP-1 or MIP-1α, may participate in modulation of HUCB
infiltration in the injury site after intravenous administration.

7.2 HUCB cells promoted microglia death under hypoxic conditions.
The above study demonstrated that HUCB cells were able to migrate
across the blood-brain-barrier under the attraction of chemokines after
intravenous administration. Once inside the brain, HUCB cells can rescue the
functional deficit caused by stroke. However, the mechanism is not clear. In a
model of stroke (26), ALS (29) and traumatic brain injury (264), the infused
HUCB cells were found in the parenchyma of the injured brain and expressed the
neuronal and astrocytic markers. These findings suggested that HUCB cells
could differentiate into neural like cells and replace the cell loss caused by injury,
which lead to the functional improvement. However, recent studies indicated that
the cell replacement mechanism was unlikely since few HUCB cells were found
in the injured brain after infusion (45). Interestingly, a decreased immune
response was observed in HUCB infused animal in comparison to the control
group (171), which could be responsible for rescuing the rat from functional
deficits caused by stroke. However, how HUCB cells modulate immune response
is not clear.

In this study, the interaction between microglia and HUCB cells was
examined. The FDA/PI assay showed that HUCB cells significantly promoted
microglial cell death during hypoxia exposure compared to the cell viability in
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hypoxic mono-cultured microglia. Accompanying the increased cell death, the
concentration of IL-1βin the hypoxia exposed co-culture medium was
significantly lower in comparison with hypoxia exposed mono-cultured group.
Hypoxia increased the amount of the pro-inflammatory cytokines IFNγ (p<0.05),
and decreased the amount of anti-inflammatory IL-10 in the HUCB and microglia
co-cultured group. Previous studies demonstrated that high IFNγcould increase
microglial sensitivity to injury, and promote cell death (165). In contrast, IL-1βis a
trophic factor for microglia. IL-1βcould prevent microglia from injury caused by
N-methyl-D-aspatate (NMDA) exposure, and promote cell recovery, while
blockage of IL-1βinhibited cell proliferation. Further, IL-1βinjection into brain
promotes astrogliosis and neovascularization at the site of injury. IL-10 is an antiinflammatory cytokine, and can protect neurons and oligodentrocytes from death
caused by glutamate (42), hypoxic-ischemia (265), LPS (266), and interferon
(266). The unbalanced state of pro-/anti-inflammatory cytokines may result in the
cell death of microglia after hypoxic exposure.

7.3 HUCB prevented neuron and astrocyte hypoxia induced cell death
Previous studies demonstrated that HUCB reduced infarct volume in the
brain of stroked animals in comparison to the untreated animal (27). This
reduced infarct volume could be the result of the reduction in inflammatory
response caused by HUCB cells. In another experiment, HUCB cells were
transplanted directly into parenchyma, where sprouting nerve fibers from the
nondamaged hemisphere were observed in the damaged side of brain in HUCB
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cell treated animals (267). In contrast, animal receiving saline did not show
obvious sprouting of nerve fibers (267). A similar effect of HUCB cells was also
observed in the model of spinal cord injury, where HUCB significantly reduced
the size of the cystic cavity at the site of injury, and an apparent sprouting of
neural axons into the injury site (268), suggesting HUCB cells have neurotrophic
effects. However, there was no direct evidence that HUCB supports astrocyte
and neuron survival under hypoxic conditions.

In this study, the effect of HUCB cells on neurons and astrocytes was
investigated. HUCB cells significantly increased neuron and astrocyte viability
after hypoxia. IFN γproduction was observed in hypoxic and normoxic coculture of neurons, while IFN γin hypoxic normoxic mono-culture was
undetectable. IFN γin hypoxia co-culture was very low. In contrast, IFN γwas
only detected in the medium of hypoxic mono-culture and normoxic co-culture of
astrocyte, and IFN γwas undetectable in other astrocyte groups. IFN γhas two
faces in intoxication and nutrition of astrocytes. As a neurotrophic factor for
astrocytes, IFN γpromotes astrocyte proliferation and even astrogliosis
(210,211). However, extensive astrocyte activation has serious side effects.
Reactive astrogliosis after CNS injury has been considered a major impediment
to axonal regeneration. IFN γalso modulates MHC class I and class II antigen
expression on astrocytes. MHC class I can elevate astrocyte susceptibility to
lysis by class I restricted T lymphocytes, and MHC class II makes astrocytes
function as antigen presenting cells, which enhances the inflammatory response
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after injury. In addition, IFN γ can induce cytotoxins including nitric oxide (212),
free radicals, TNFα, IL-1βproduction, and all of them may exacerbate the brain
damage. As a neurotrophic factor for astrocytes, the low level of IFN γ in
astrocyte hypoxic co-culture increased the vulnerability of astrocytes exposed to
hypoxia. Our results suggested that HUCB cells could suppress astrocyte activity
under hypoxic conditions, which in turn may inhibit the inflammatory responses.
While in neuronal cultures, IFN γwas only found in the co-culture conditions, and
the level of IFN γin hypoxic co-culture groups was very low, which may not affect
neuronal viability during hypoxia

Our data also indicated that no IL-1βwas detected in astrocyte medium. In
addition, the level of IL-1β was very low in the medium of neuron culture. As a
pro-inflammatory cytokine, IL-1β is toxic to neurons and astrocytes. It has been
demonstrated that IL-1β could increase the calcium entry into the cell, which is
strongly implicated in cell death (238). In addition, exogenous administration of
IL-1β into animal brain injured through trauma, ischemia, or excitotoxic stimuli
markedly increased the extent of injury (203), while neutralization of IL-1β with its
antibody or IL-1βreceptor antagonist markedly decreased the brain injury
resulting from MCAO or intracerebral injection of toxic chemicals (269). The toxic
effect of IL-1βwas dependent on concentration. When its concentration was high,
IL-1βhad a neural protective profile, such as inhibition of glutamate release,
inhibition of calcium entry and enhancement of synaptic inhibition by γaminobutyric acid (GABA) (201). In our study, IL-1βconcentration was low in all
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groups, and was not likely involved in neuron and astrocyte cell survival or cell
death.

In contrast to IL-1β, IL-6 was not detectable in the neuronal culture, and it
was only observed in the medium of co-cultured astrocytes. There was a great
significant difference of IL-6 between hypoxic co-cultured astrocytes and
normoxic co-cultured astrocytes (*, p<0.05). Interestingly, the anti-inflammatory
cytokine IL-10 was higher in co-cultured neurons under hypoxic conditions in
comparison to other groups. The similar results were observed in astrocyte
culture. It is well known that IL-6 has a neural protective effect against the injury
caused by glutamate, or N-methyl-D-aspartate (NADA) (219), and induced
astrogliosis in vitro (220). When IL-6 was blocked with an IL-6 competitive
inhibitor, the neuroprotective effect disappeared (270). Similar to IL-6, IL-10 has
a neuroprotective function against lipopolysaccharide (LPS) induced neuronal
damage (271). Interestingly, IL-10 can promote glial cell proliferation at high
concentration, while it inhibits DNA replication of glial cells at low concentration
(272). In our study, IL-6 and IL-10 may provide protective effects to astrocytes
and neurons exposed to hypoxia.

7.4 The interaction between the HUCB subpopulation and neural cells
Our studies have demonstrated that HUCB can prevent neurons and
astrocytes from hypoxia- induced cell death, and promote microglia cell death
under hypoxic conditions. These effects were accompanied by modulation in the
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pro-/anti-inflammatory cytokines such as IFNγ, IL-1β, IL-6 and IL-10 between
HUCB and neural cells. However, which subpopulation of HUCB produces these
effects is not known. In this study, T cells (CD8+), B cells (CD19+) and
monocytes (CD11b+) were isolated from HUCB by magnetic cell sorting. These
cells were cultured with/without neurons, astrocytes and microglia under
normoxic and hypoxic conditions respectively. Cell viability and cytokine
expression were examined.

Interestingly, there were differences in the effect of the subpopulation on
neurons, astrocytes and microglia. B cells (CD19+) and monocytes (CD11b+)
HUCB cells decreased microglia survival after hypoxia compared to survival in
microglial monoculture. In contrast, the CD8+ T cells significantly decreased
astrocyte cell viability after hypoxia exposure compared to viability in astrocyte
monoculture. The concentrations of IFNγ, IL-10, IL-6 and IL-1βdid not
significantly change in any of these cultures, suggesting they may not be critical
players in the observed cell death.

No neuroprotective effect was observed in either B cells, T cells or
monocyte co-cultured with neurons. The reason is not clear. It is possible that the
interaction between HUCB subpopulation is needed to induce neurotrophic
effects of HUCB for neural survival under hypoxic exposure.
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